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“Science, my lad, is made up of mistakes, but they are mistakes which it is useful 
to make, because they lead little by little to the truth.” 
 





Charcot-Marie-Tooth disease is the most common neuromuscular disorder, with a 
prevalence of 1:2500. Despite the phenotypical similarities among patients, it is 
characterized by a remarkable genetic heterogeneity. Among the different genes 
that are responsible for CMT, mutations in Myelin Protein Zero (MPZ) gene cause 
CMT1B and represent the 5% of all CMT cases. MPZ gene encodes for the P0 
protein, the principal myelin protein of the peripheral nervous system; at the 
moment, more than 200 mutations in these gene are known and almost all 
mutations are pathogenic. The phenotype of MPZ related neuropathies is also 
variable, implying multiple pathogenic mechanisms. We focused our interest on 
misglycosylation, which is increasingly recognized as a cause of different 
diseases, but has never been investigated in inherited neuropathies, even if 
peripheral myelin is largely composed of glycoproteins. 
We identified two groups of mutations in MPZ gene: one group is composed by 
variants introducing a new glycosylation site in the P0 sequence, the other one 
includes mutations that eliminate the constitutive glycosylation site of the P0 
protein. Through transient transfection in different cellular lines (HeLa cells and 
Schwannoma rat cells), and through different techniques of cell and molecular 
biology, we founded that mutant protein with a double oligosaccharide are 
partially retained intracellularly, with consequences on their adhesion capacity; 
instead, mutant proteins that loose the constitutive glycosylation site were less 
affected in localization or adhesion capacity. To further investigate how peripheral 
myelination is affected by misglycosylation, in particular, we generated a mouse 
model carrying the mutation D
61
N to evaluate in vivo the effects of 
hyperglycosylation. This mouse model, that represent the first knock-in model of 
CMT1B generated using the CRISPR/Cas9 technology, faithfully recapitulates the 
human pathology and confirms hyperglycosylation as a novel pathomechanism 
for CMT1B. We characterized the mice with behavioral test and with 
electrophysiological analysis, finding a severe impairment in nerve functionality; 
this was further confirmed by morphological analysis that revealed a 
de/dysmyelinating phenotype with the presence in sciatic nerves of myelin 
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abnormalities similar to tomacula structures. Starting from evidences founded in 
literature, we evaluated the possibility to test a molecule, belonging to a class of 
compounds called iminosugars, that are potentially able to inhibits some enzymes 
involved in glycosylation cascade, and that are already used for the treatment of 
other pathologies. We obtained encouraging results from the treatment of cells 
transfected with the D
61
N mutation, in terms of protein localization and 
adhesion capacity; also the treatment of mutant DRGs that were characterized by 
myelin abnormalities, ameliorated the morphology. However, more in depth 
experiments showed that this molecule didn't act modifying the glycosidic 
structure but decreasing the amount of myelin proteins. 
The ineffectiveness of the treatment showed that, before proceeding, it is 
necessary to know the glycosidic composition of the new oligosaccharide but also 
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The nervous system can be divided in two parts: the Central Nervous System 
(CNS) and the Peripheral Nervous System (PNS). The CNS is formed by brain 
and spinal cord, whereas the PNS is constituted by fibers that convey informations 
from both external environment and internal organs to the CNS or from the CNS 
to muscles, organs and glands. 
The nervous system is mainly constituted by two types of specialized cells: 
neurons and glial cells, even if cells of the immune system, blood cells and 
fibroblasts are also present. Glial cells are located near neuron cell bodies and 
axons and they have the important role to guide axonal growth and to form 
myelin. The principal role of the myelin is to insulate axons to allow a rapid 
impulse propagation, necessary for motor, sensory and cognitive function of the 
nervous system; the myelin ensheathment of axons provides the structural basis 
for saltatory action potential propagation [1-5]. Neuronal signals are transmitted 
in the form of electrochemical waves, called action potentials that travel along the 
axons and reach specific target cells via electrical or chemical synapses. 
Myelin is a multilamellar structure present both in the CNS and in the PNS. In the 
CNS, myelin is formed by oligodendrocytes [6] whereas in the PNS it is formed 
by Schwann Cells (SCs) [7]. Glial cells, that have different developmental origin 
(neural crest for SCs and subventricular zone for oligodendrocytes), enwrap the 
axons forming myelin as a protrusion of their own plasma membrane; however, 
SCs and oligodendrocytes differ for the number of myelinated axonal segment per 
myelinating cell: oligodendrocytes contact multiple axons simultaneously in order 
to form myelin (60:1), whereas SCs enwrap one axon at time (1:1) and provide 
myelin to a single internode, i.e. the space included between two nodes of Ranvier 








At the electron microscope, in transversal sections, the myelin appears as a spiral 
extension of a glial plasma membrane (Figure 2A, B) and present a dark zone, 
called electron-dense “major dense line” (MDL) and a clearer area called 
“intraperiod line” (IPL) (Figure 2C). Longitudinally, the myelin sheath 
surrounding each internode can be divided into compact and non-compact myelin. 
The non-compacted myelin is composed by mesaxons, paranodal loops and 
Schmidt-Lanterman incisures. The paranodal loops, in particular, are responsible 
Figure 1: Schematic representation of the structure of myelinated axons. Myelinating 
glial cells, oligodendrocytes in the CNS and Schwann cells in the PNS, form the 
myelin sheath by enwrapping their membrane several times around the axon. 
Myelinated tracts (internodes) are interspersed with gaps, the nodes of Ranvier. 
Oligodendrocytes can myelinate different axons and several internodes per axon, 
whereas Schwann cells myelinate a single internode in a single axon (Part of Poliak, 
S. and E. Peles 2003). 
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for myelin anchorage to the axon and the correct structure of the nodes. The 
Schmidt-Lanterman incisures seem to be the connections between inner and outer 
compacted myelin (Figure 2D). Finally, Cajal bands are cytoplasmic 
compartments on the abaxonal surface of SCs, required for the longitudinal 
extension of the myelinated internode [9-11]. 
 
Figure 2: Myelinated axons in PNS and CNS. 
A) Electron microscopy of a peripheral sciatic nerve with a myelinating Schwann Cell 
forming consecutive wrapping around the axon. 
B) Electron microscopy of an optic nerve in which oligodendrocyte myelinate 
multiple axonal segments. 
C) Magnification of myelin in which are distinguishable the intraperiod lines (IPL) 
and the major dense line (MDL). 
D) Schmidt-Lanterman incisures provide cytosolic channels through compact 
peripheral myelin. (Adapted from Nave, K.A. and H.B. Werner 2014). 
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Furthermore, the Node of Ranvier (Figure 3) is a non-insulated axonal segment 




 channels that are 
essential for the generation of the action potential [12]. Nodes of Ranvier have a 
central role in the conduction of the electric impulse along the axon also because 
myelin is a very lipid rich compartment, which blocks the passage of water and of 




. The nerve impulse is a self-regenerating electrical 
current that travels along the axon due to ion movements. The action potential is 
first generated in the nerve cell body, then the current moves quickly towards the 
internode. Along the internode, there is electrotonic spread of depolarization of 
the axonal membrane [13, 14]. At the next node of Ranvier this depolarization 
leads to the opening of the sodium channels clustered in the Node of Ranvier, 
allowing the entrance of positive ions that regenerate the action potential. At the 
juxtaparanodal level, instead, the exit of the K
+
 ions re-polarizes the membrane. 
The wave generated from the entrance of positive sodium ions in the axon, can 
again passively diffuse along the internode to the following node of Ranvier, 
where the action potential is newly re-generated. In this way the “saltatory” 
conduction of the impulse is generated, as the action potential seems to leap from 
one node to the next one [15]. In the unmyelinated axons generation of the action 
potential follows the same process, even if the propagation of the signal is 25-fold 
slower. The main difference is that in the unmyelinated fibers, sodium channels 













2. MYELIN IN THE PERIPHERAL NERVOUS SYSTEM 
2.1 PNS MYELINATION 
In vertebrates, SCs originate from a population of multipotent cells derived from 
the neural crest, a transient group of cells that delaminates from the neural tube 
during embryonic development [16]. Cells of the neural crest also give rise to 
other cell types, such as neurons of the sensory, sympathetic and parasympathetic 
ganglia, chromaffin cells and melanocytes. How the glial lineage originates from 
the neural crest is still unclear, even if appeared that many crest cells have entered 
glial lineage at the onset of cell migration. In vivo and in vitro studies showed the 
instructive signals that regulate crest diversification: one of these signal seems to 
be Neuregulin-1 that block the entry to the neuronal lineage [17, 18]. 
The final goal of SCs development is the formation of myelinating and non-
myelinating cells ensheathing large and small diameter axons, respectively. 
However, this events are preceded by the generation of other two cells types: 
Schwann cell precursors, which are the glial cells that migrate from neural crest 
during embryonic (E) day 14-15 in rat (mouse E12-13), and immature Schwann 
cells, which derive from the proliferation of SC precursor during E15 to E17 in rat 
(mouse E13-15) until the time of birth. At this point, immature SCs mature and 
their fate depends on the diameter of the axon they contact: in fact, all mature SCs 
are potentially able to form myelin by establishing a one to one relationship with 
axon. However, when mature SCs contact axons with a diameter greater than 1 
µm, they form myelin (myelinating Schwann cells), instead, when they contact 
small calibre axons, they surround them forming Remak boundles (non 
myelinating Schwann cells) [19] [20] (Figure 4). 
Figure 3: Schematic longitudinal cut of a myelinated fiber around the node of 
Ranvier. The node is contacted by Schwann cell microvilli in the PNS or by processes 
from perinodal astrocytes in the CNS. Myelinated fibers in the PNS are surrounded by 
a basal lamina. The paranodal loops form septate-like junctions (SpJ) with the axon. 
The juxtaparanodal region, surrounded by compact myelin, is adjacent to the 
paranode. The internode extends from the juxtaparanodes and is also wrapped by 




The final nerve morphogenesis is reached also with the contribution of immature 
SCs that, in a process called radial sorting, separate axon according to diameter; 
indeed, they signal to perineurial cells and other nerve components to promote 
their differentiation. Radial sorting is an important process that serves to separate 
large caliber axons intended to be myelinated, from small caliber axons, which 
will be part of Remak bundles, and involves different steps: first, axons are 
grouped in bundles by a “family” of 3-8 immature SCs that deposit a common 
basal lamina around them; then there is the recognition of large caliber axons, the 
radial segregation of large axons to the periphery, the defasciculation and 
establishment of 1:1 relationship between an axon and a promyelinating Schwann 
cells. The promyelinated SC will differentiate into a myelinating SC, while the 
SCs in contact with small caliber axons will surround them and differentiate into a 





Figure 4: Schwann cell lineage. Schematic representation of the main cell types and 
developmental transitions occurring during Schwann cell development (Jessen, KR. 
and Mirsky, R. 2005). 
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The interaction between axons and glial cells is fundamental for nervous system 
development. Axonal signals control SC migration, survival and proliferation to 
guarantee the correct SC-axon match; indeed, axons regulate SC differentiation 
into myelinating and non-myelinating population [19]. On the other hand, SCs 
provide trophic support for the development of neurons and control axonal 
properties [23]. Signals deriving from SCs guide the assembly of multi-protein 
complexes, such as cell adhesion molecules, ion channels and scaffolding 
proteins; myelinating SCs regulate the axon cytoskeleton, organelle content and 
rates of axonal transport [24]. Finally, interaction between axons and SCs has an 
important role after axonal damage. For example, during Wallerian degeneration 
axons degenerate distally and, in parallel, distal SCs de-differentiate to an 
immature stage. At this point, glial cells proliferate and fill the endoneural basal 
lamina tube (bands of Bungner) required for axonal regeneration. After re-
contacting axons, SCs stop proliferating [25, 26]. 
The regulation of radial sorting and SCs differentiation require extracellular 
component and signalling pathways that control polarity, cytoskeletal remodelling 
and proliferation [21, 22, 27, 28]. The main pathway that regulates SC 
development in the PNS is the NRG1/ErbB2-3 signalling [29-31]. In particular, 
the axonal NRG1 type III, among all NRG1 isoforms expressed in the PNS, 
determines the fate of SC differentiation in both myelinating and non-myelinating 
SCs and regulates myelin thickness [32, 33]. Other important players that regulate 
Figure 5: Development of myelinating and non-myelinating Schwann cells. 
Representation of radial sorting process that separates large diameter axons from 
small diameter axons (Monk, KR. et al. 2015). 
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SC myelination are the Notch1 signalling [34], BDNF and NT-3 neurotrophins 
[35], the Necl family of proteins [36] and GPCR receptors such as GPR126 [37] 
and GPR44 [38]. Important signalling pathways downstream these molecules are 
the PI-3 Kinase/AKT/mTOR pathway [39, 40], the ERK/MAPK pathway [41, 
42], the cAMP signalling [43] and the Calcineurin/NFAT signalling [44]. Both 
positive and negative regulators of myelination have been identified [24, 45]. 
Among positive transcriptional regulators, the transcription factor Sox10 is 
responsible for precursor SC differentiation, SCs maturation and myelin 
maintenance during adulthood, together with Krox20/Egr2 [46, 47]. Along with 
Sox10, the POU domain transcription factors Oct-6 and Brn2 [48] control the 
expression of Krox20, the master regulator of SC myelination in vitro and in vivo 
[49]. Krox20 directly represses negative regulators of PNS myelination, in 
particular Sox2 and Id2, and activates myelin genes expression in SCs [26, 49]. 
 
2.2 MYELIN COMPOSITION 
Myelin has a peculiar biochemical composition: ~70-80% of myelin dry-weight is 
composed by lipids, that guarantee the insulating properties of myelin sheaths; 
instead, the remaining ~20-30% of myelin dry-weight is constitute by proteins, 
whose role is to maintain myelin compaction, stability and functionality. 
 
2.2.1 Lipids in PNS myelin 
The principal lipid classes, such as neutral lipids, phosphoglycerides and 
sphingolipids, are present in myelin membranes, even if there are no myelin-
specific lipids. Myelin lipids and glycoproteins are synthesized in the 
Endoplasmic Reticulum (ER) and altered ER homeostasis impairs lipid biogenesis 
suggesting a tight coordination between the two biosynthetic events [50]. 
Cholesterol represent 20-30% of the total lipids in PNS myelin. In mouse sciatic 
nerves, this lipid accumulates throughout the period of neo-myelinogenesis and 
during the period of myelin maturation; the accumulation of the cholesterol can be 
explained taking into account the proposed role in stabilization and compaction of 
the multilamellar myelin membrane [51, 52]. The importance of this lipid is 
 15 
demonstrated by the fact that mice in which there is a reduction in cholesterol 
synthesis develop hypomyelination [53]. 
The other kind of most represented lipids are phospholipids, which account for 
40% of the total lipid content. Finally, glycosphingolipids, a subclass of 
glycolipids, are the most myelin-specific type of lipids and include 
Galactosylceramide (GalC), which represents 20% of the total dry mass of 
myelin. 
 
2.2.2 Proteins in PNS myelin 
Differently from the lipids, in PNS myelin there is a very specific set of proteins 
(Table 1 and Figure 6). At least 60% of the proteins are glycoproteins, 20-30% of 
total proteins have basic properties, while the remaining 10-20% is a 
dyshomogeneous group of proteins with very low levels of expression such as 
CNP, PLP and Connexin 32 [2, 15, 54]. 
 
The main proteins are: 
Myelin Basic Protein (MBP): MBP is expressed in both PNS and CNS. In mouse 
the gene coding for MBP is composed by seven exons on chromosome 18. The 
transcriptional regulation of MBP is characterized by an alternative splicing that 
produces different MBP protein isoforms with diverse molecular weights and 
developmental regulation [55, 56]. In the PNS four MBP isoforms of 21.5, 18.5, 
17 and 14 kDa have been described [57]. MBP accounts for 5-15% of all PNS 
Table 1: Protein composition of peripheral nerve myelin (Garbay, B. et al. 2000). 
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myelin proteins and localizes in the major dense line of compact myelin. MBP has 
an important role in the compaction and maintenance of myelin itself via 
interactions with the lipids of the membrane; however, MBP is not necessary for 
the formation of myelin lamella in the PNS [58]. Maybe for these reason, 
transgenic mice lacking MBP showed minimal signs of PNS myelin alterations 
[59], while the absence of the protein in the CNS severely impairs myelin 
compaction [60]. 
Peripheral Myelin Protein 22kDa (PMP22): PMP22 is a 22 kDa glycoprotein 
that represent 2-5% of total PNS myelin proteins [61]. The gene encoding for 
PMP22 is on chromosome 17 in humans and chromosome 11 in mice, and 
contains six exons. The predicted amino acid sequence of PMP22 defines four 
transmembrane domains, two extracellular loops (ECL1 and ECL2), a N-terminus 
into the membrane bilayer and a cytoplasmic C-terminus [62]. The protein is 
synthesized into the ER and, after synthesis, it undergoes post-translational 
modifications and folding reactions, such as the N-glycosylation on asparagine 41, 
an amino acid of the first extracellular loop, before entering the Golgi 
compartment and being trafficked to the myelin sheath. The turnover of the 
protein is very rapid, its half-life is about 1 hour and up to 50% of the newly 
synthesized protein is degraded by the proteasome, while only a small portion can 
reach the cell surface [63, 64]. PMP22 is localized in the compacted myelin with a 
dual role of myelin formation and maintenance [65, 66]. The two extracellular 
loops are thought to be responsible for the adhesiveness of PMP22, while 
extracellular domains (ECD) were suggested to mediate both homophilic 
interaction between PMP22 molecules and heterophilic interaction with P0 [67, 
68]. However, the protein is ubiquitously expressed also in non-neural tissue, 
suggesting alternative roles for PMP22 [69]. 
Expression of PMP22 is strictly regulated. Indeed, misregulation of the protein 
levels causes neuropathy in both humans and mice [70, 71]. In particular, deletion 
of the gene causes a HNPP (Hereditary Neuropathy with Pressure Palsy) [61], 






3. MYELIN PROTEIN ZERO 
Myelin Protein Zero (P0) is the most abundant protein in the PNS. It represents 
around 20-50% of all the proteins synthesized by SCs [73] and its principal role is 
to mediate myelin compaction [58]. 
 
3.1 THE MPZ GENE 
P0 protein is encoded by the MPZ gene; the gene is located on chromosome 1, in 
humans and in mice, and is divided into six exons distributed along 7kb of DNA 
[74-76]. MPZ is expressed by SCs mainly during myelination although its 
expression is detectable also in neural crest cells, in precursor SCs, in immature 
SCs and in non-myelinating SCs [77]. P0 protein is expressed from the start of 
myelination, around birth, specifically in myelinating SCs, and the expression 
reaches the peak between P21 and P28; finally, the level of expression decreases, 
but remaining still significant during adulthood [78, 79]. 
The expression of P0 at high levels, and the maintenance of the expression, 
depend on the contact of SCs with axons [80]. Different factors can regulate MPZ 
expression both in vitro and in vivo: axons can regulate P0 expression through 
intracellular stimuli such as cAMP [81], via interaction between cytoskeleton and 
SC basal lamina [82], via hormone stimulation [83] or via NRG-1 type III [33]; 
negative regulators have been also detected, such as the treatment with glial 
growth factor (GGF), tumor growth factor β (FGF β) and fibroblast growth factor 
Figure 6: Schematic representation of the most abundant proteins localized in 
compact myelin of peripheral nerves (Part of Baumann, N. and Pham-Dinh, D. 2001). 
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2 (FGF 2) [84, 85]. Finally, Oct6, SOX10 and Krox20 are transcription factors 
that regulate P0 transcription: Oct6 is expressed highly before myelination [86], 
Krox20 is expressed mainly in promyelinating and myelinating SCs [87], while 
SOX10 can activate Krox20 expression and the consecutive MPZ expression 
during myelination [88, 89]. 
 
3.2 P0 PROTEIN STRUCTURE AND SYNTHESIS 
P0 is a transmembrane glycoprotein that belongs to the Immunoglobulin (Ig)-like 
superfamily [90]. The protein has a molecular weight of ~29 kDa and the P0 
sequence consists of 248 amino acids (aa) that can be divided in three domains: an 
N-terminal extracellular domain (ECD; aa 30-153), a single transmembrane 
domain (TMD; aa 154-179) and a C-terminal intracellular cytoplasmic domain 



















Figure 7: Schematic representation of P0 protein (Adapted from Makowska, A. 
2007). 
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P0 is synthesized by the ribosomes associated to ER membranes, is processed 
through ER and in the Golgi compartment, is sorted into specific vesicles and 
transported to myelin sheaths via a microtubule dependent pathway. P0 synthesis 
and maturation are very rapid, in about 30 min the protein is synthesized and 
incorporated into the myelin sheaths [93]. The first 29 aa of the extracellular 
domain encode for the hydrophobic signal peptide that drives the synthesis of P0 
through the ER, where the signal peptide is cleaved by ER proteases [90]. The 
remaining part of the extracellular domain is constituted by ten β-strands 
organized in two β-sheets; the two β-sheets are linked to each other by the 
formation of a disulphide bond between Cystein 50 and Cystein 127 [94, 95]. In 
the extracellular domain is also present the glycosylation sequence Asn122-X-
Thr124; analysis of rabbit sciatic nerves revealed that the carbohydrate is N-
linked to asparagine 122 and is composed of a single, nine-sugars chain, including 
one sialyl, one galactosyl, one fucosyl, three mannosyl and three N-
acetylglucosamine moieties [96-98]. The ECD contains a sequence that is the 
more conserved, SDNGT (aa 120-124) that has a role in mediating homophilic P0 
interaction; however, crystal structure analysis of P0 indicates that this region is 
also implicated in the formation of P0 homotetramers in trans [94], keeping 
















The transmembrane domain, highly hydrophobic, contains a glycine sequence 
important for protein dimerization, while the C-terminal cytoplasmic domain is 
the most basic region of the protein and undergoes acylation at C153 and 
phosphorylation on several residues [99, 100]. Finally, the cytoplasmic domain 
contains a sequence YAML (aa 220-223), that targets P0 for microtubular 
transport to the myelin sheath [99]. 
 
3.3 P0 FUNCTION 
The principal function of P0 is to mediate compaction of adjacent wraps of 
myelin, forming the intracellular “major dense line” and extracellular intraperiod 
line. In vitro and in vivo studies showed that P0 is essential for normal wrapping, 
compaction and maintenance of peripheral myelin. Expression of the protein in an 
ectopic system, like CHO cells, caused adhesion between different cells and the 
formation of aggregates, supporting the hypothesis that the extracellular domain, 
which presents homology with members of the immunoglobulin superfamily, 
plays a role in homophilic interactions [90, 101]. Many data about the role of P0 
have been obtained from P0 knock out and P0/+ mice [58, 102, 103]. Peripheral 
nerves from P0 KO mice are characterized by hypomyelination and myelin 
uncompaction, with a reduced SC number and increased number of axons without 
myelin. Nerves of P0 KO mice also presented active demyelination and the 
formation of “onion bulbs”, formed by concentric layers of a SC cytoplasm 
surrounding the axon but no in contact with it [58]. P0/+ nerves presented a 
milder phenotype compared to P0 KO, characterized by normal development, but 
slow demyelination with aging [104]. 
P0 not only has a structural role in myelin, but is also important for the regulation 
of myelination: the absence of P0 causes the misregulation of other myelin genes, 
such as PMP22, whose expression is reduced, and MAG, whose expression is 
increased [102, 105]. Beside altering myelin gene expression, the absence of P0 
caused also the mislocalization of junctions [106], suggesting that P0 can regulate 
Figure 8: Crystallographic model of putative tetramers formed via interaction of the 
extracellular domain of P0 (Part of Shapiro, L. 1996). 
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SCs polarization, junction distribution and gene expression during myelination; 
indeed, P0 can participate in inside-outside signalling to mediate adhesion. 
 
4. CHARCOT-MARIE-TOOTH DISEASE 
Charcot-Marie-Tooth (CMT) disease and related neuropathies represent a 
heterogeneous group of hereditary disorders, with more than 90 genes associated, 
many of which have been discovered in the last few years thanks to the next 
generation sequencing (NGS) technology. 
 
4.1 CLINICAL FEATURES AND CLASSIFICATION OF CMTs 
Named after the three physicians who first characterized this disorder in the late 
19
th
 century, CMT disease is the most common inherited neurological condition 
with a prevalence of around 1:2500 [107, 108]. 
The disease presents common clinical phenotype (Table 2): onset usually occurs 
in the first two decades of life with a subsequent slow progression over decades. 
However, late onset mild forms or highly severe early onset CMTs have been 
reported, the latter known as Dejerine-Scottas syndrome (DSS) or Congenital 
Hypomyelination (CH), based on different pathological hallmarks. Motor and 
sensory symptoms gradually affect the leg, producing the typical distal atrophy 
and sensory loss of the lower limbs, later spreading to the hands. Patients develop 
skeletal abnormalities, pes cavus, distal sensory loss, reduced/absent deep tendon 
reflexes, distal muscle weakness and atrophy, impaired proprioception, balance 
difficulty and, in some cases, neuropathic pain [108-110]. Using 
neurophysiological parameters, CMTs can be divided into two main different 
groups: a demyelinating form, CMT1, characterized by reduced nerve conduction 
velocities (<38 m/s) and myelin abnormalities; an axonal form, CMT2, with 
normal or mildly slowed nerve conduction velocities (>38 m/s) and evidence of 








Is possible to divide the CMTs also based on the mode of inheritance: autosomal 
dominant demyelinating CMT is indicated as CMT type 1 (CMT1), autosomal 
dominant axonal CMT is CMT type 2 (CMT2), X-linked CMT is CMTX, and 
autosomal recessive CMT is CMT type 4 (CMT4). Since the continuous discovery 
of genes associated with CMT, the new subtypes have been defined by the 
addition of a letter after the number of a specific type of CMT [113]. CMT is 
Inheritance Phenotype Mutated genes
CMTX X-linked
CMTX1: men more affected than women; motor NCV commonly 
intermediate in men (30–45 m/s) and in the lower range of CMT2 in 
women; NCV slowing can be non-uniform and asymmetrical. Nerve 
biopsy: axonal loss and some demyelination, few onion bulbs; 
occasional CNS involvement
Other CMTX types: only males affected
GJB1/Cx32, PRPS1
Intermediate CMT AD
Mild to moderate severity. NCVs intermediate between CMT1 and 
CMT2 (25–45 m/s). Pathological features of both CMT1 and CMT2 
MPZ, DNM2, YARS, 
(NEFL)




Severe visual loss with optic atrophy NCVs preserved or mildly 
slowed
MFN2
AD=autosomal dominant. AR=autosomal recessive. BSCL2=Berardinelli-Seip congenital lipodystrophy type 2. CHN=congenital 
hypomyelinating neuropathy. CMT=Charcot–Marie–Tooth disease. CMTX=X-linked CMT. DCTN1=dynactin. dHMN=distal hereditary motor 
neuronopathy. DNM2=dynamin 2. EGR2=early-growth-response 2. DSN=Déjèrine-Sottas neuropathy. FGD4=FGD1-related F-actin binding 
protein. FIG4=FIG4 homologue of Saccharomyces cerevisiae. GARS=glycil-tRNA synthetase. GDAP1=ganglioside-induced differentiation-
associated protein 1. GJB1/Cx32=gap junction B1/connexin 32. HMSN=hereditary motor and sensory neuropathy. HSPB1/HSP27=heat shock 27-
kDa protein 1. HSPB8/HSP22=heat shock 22-kDa protein 8. IGHMBP2=immunoglobulin mu binding protein 2. KIAA1985/SH3TC2=SH3 
domain and tetratricopeptide repeat domain 2. LMNA=lamin A/C nuclear envelope protein. MED25=mediator of RNA polymerase II 
transcription, subunit 25. MFN2=mitofusin 2. MPZ=myelin protein zero. MTMR2=myotubularin-related protein 2. NCV=nerve-conduction 
velocity. NDRG1=N-myc downstream-regulated gene 1. NEFL=neurofilament light chain. PMP22=peripheral myelin protein 22. 
PRPS1=phosphoribosylpyrophosphate synthetase 1. PRX=periaxin. RAB7=small GTPase late endosomal protein RAB7. SBF2/MTMR13=set-
binding factor 2/myotubularin-related protein 13. SIMPLE/LITAF=small integral membrane protein of lysosome/late endosome; 
lipopolysaccharide-induced tumour necrosis factor-alpha factor. YARS=tyrosyl-tRNA synthetase.
dHMN
AD or AR       
X-linked
Pure motor involvement on clinical, electrophysiological, and 
morphological basis Preserved or mildly slowed NCVs; >38 m/s in 
upper-limb motor nerves; normal sensory action potential
Sural nerve biopsy normal or near-normal







Pyramidal involvement ranges from increased deep-tendon reflexes 
with Babinski sign to spastic paraplegia
Electrophysiology: usually axonal loss; reduced sensory action 
potential amplitudes
MFN2, BSCL2, GJB1
CMT3 (HMSN III; 
DSN-CHN)
AD or AR
Early onset; more severe than CMT1
Very slow NCVs
Nerve biopsy: dysmyelination, onion bulbs
CHN: congenital onset, extreme severity, hypomyelination
PMP22, MPZ, EGR2, 
PRX
CMT4 AR
Earlier onset and more severe course than CMT1
Vocal cord paresis, sensorineural deafness, and facial and 
diaphragmatic weakness can occur




NDRG1, EGR2, PRX, 
FGD4, FIG4
Usually typical clinical phenotype
Uniform and diffuse motor and sensory NCV slowing (<38 m/s in 
upper-limb motor nerves)
Nerve biopsy: onion bulbs or other myelin abnormalities; secondary 
axonal degenerationabnormalities; secondary axonal degeneration
PMP22 duplication, 





Normal or slightly reduced NCV (>38 m/s in upper-limb motor 
nerves) and decreased amplitudes
Nerve biopsy: chronic axonal neuropathy usually without any 
specific diagnostic featuresneuropathy usually without any specific 
diagnostic features
CMT2 AD or AR
MFN2, MPZ, NEFL, 
HSPB1 (HSP27), HASB8 
(HSP22), RAB7, GARS, 
GDAP1 (AD/AR), LMNA 
(AD/AR), MED25 (AR)
Table 2: CMT subtypes with their associated phenotype (Adapted from Pareyson, D. 
2009). 
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caused by mutations in genes that encode for different proteins, that are involved 
in different functions, such as myelin compaction and maintenance or 
cytoskeleton formation, axonal transport or mitochondrial metabolism [114, 115]. 
Many studies found that about 90% of patient with CMT had a mutation in one of 
these gene: PMP22, GJB1, MPZ, MFN2 or GDAP1 (Table 3) [116]. 
The most common CMT type, accounting for ~50% of all CMTs, is CMT1A 
caused by duplication of 1.4 Mb on chromosome 17p11.2, a region that includes 
the PMP22 gene; less commonly, CMT1 is caused by point mutations in PMP22 
or in MPZ gene (5% of CMT cases) [117, 118]. CMTX1 is the second most 
common CMT type (~15-20% of all patients) and is caused by mutation in the 
gap-junction B1 (GJB1) gene, which encode for Connexin-32 [119]; instead, 
CMT2 has an heterogeneous genotype without a prevalent gene involved: the 
most often mutated gene is Mitofusin 2 (MFN2), followed by mutations in MPZ 
and in Neurofilament Light Chain (NEFL) [120]. 
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Compact myelin protein; adhesion role
SIMPLE/LITAF CMT1C
Schwann-cell cytoplasm; stimulator of monocytes and macrophages; causes secretion of 





Schwann cells; transcription factor; activates transcription of several myelin-associated 
genes; plays a part in peripheral nervous system myelin development and maintenance
NEFL
CMT1F, CMT2E
Cytoskeleton; neurofilament organisation; axonal transport
GJB1/Cx32 CMTX1 Schwann cells, oligodendrocytes; gap-junction-forming protein in non-compact myelin
PRPS1 CMTX5
Ubiquitously expressed in human tissues, including cochlea; mediates biochemical step in 
purine metabolism and nucleotide biosynthesis; mutation causes reduced enzyme activity
DNM2 DI-CMTB Family of large GTPases; part of cellular fusion–fission of cellular membrane apparatus
YARS DI-CMTC
Ubiquitous expression, including brain and spinal cord; concentrated in granular structures 
in growth cones, branch points and distal neuritis; aminoacil tRNA synthetase, catalyses 




Mitochondrial outer membrane and endoplasmic reticulum; fusion of mitochondria and 
endoplasmic reticulum–mitochondria interactions
RAB7 CMT2B
Late endosomes; family of RAS-related GTP-binding proteins; regulator of vesicular 
transport and membrane trafficking; might have a role in linking vesicles and target 
membranes to the cytoskeleton
GARS CMT2D, dHMN V Ubiquitous expression; aminoacyl tRNA synthetases; protein synthesis
HSPB1 (HSP27) CMT2F, dHMN
Member of the small heat shock protein family; regulation and maintenance of cytoskeleton; 
interacts with intermediate filament proteins
HSPB8 (HSP22) CMT2L, dHMN II
High expression in motor and sensory neurons of spinal cord; member of the small heat 
shock protein family; interacts with heat shock binding protein 1 ; mutated protein promotes 




Expressed in neurons (brain and spinal cord) and Schwann cells; localised in mitochondria; 
function might be associated with the maintenance of the mitochondrial network
LMNA CMT2B1 Intermediate filament; structural protein of the nuclear lamina network; gene transcription 
MED25 CMT2B2
Subunit of the human activator-recruited cofactor, a family of large transcriptional 
coactivator complexes related to the yeast mediator; exact physiological function in 
transcriptional regulation remains obscure
MTMR2 CMT4B1
High levels in neurons, myelinating and non-myelinating Schwann cells; belongs to the 
myotubularin family; dephosphorylates phosphatidylinositol 3-phosphate and 
phosphatidylinositol 3,5-bisphosphate
SBF2/MTMR13 CMT4B2
Belongs to the myotubularin family; phosphatase, involved in phosphoinositides 
metabolism; possibly associated with control of myelination
KIAA1985 (SH3TC2) CMT4C Neural tissues, including peripheral nerve; possible role in assembly of protein complexes
NDRG1 CMT4D
Ubiquitous expression, high levels in Schwann cells; possible functions are growth arrest 
and cell differentiation, and signalling protein shuttling between cytoplasm and nucleus 
PRX CMT4F, DSN
Membrane protein of Schwann cells; interaction between plasma membrane, proteins, and 
cytoskeleton; maintenance of peripheral nerve myelin
FGD4 CMT4H
Cytoplasm; binds along sides of actin fibres; family of Rho GDP/GTP nucleotide exchange 
factors; alters Schwann cell shape: induces formation of filopodia and lamellipodia; possible 
disease mechanism: impaired Rho GTPase signalling
FIG4 CMT4J
Vacuolar membrane localisation; phosphatase, involved in phosphoinositides content and 
vesicular trafficking
BSCL2
dHMN V, Silver 
syndrome, CMT2
Seipin, membrane protein of the endoplasmic reticulum, widely expressed in the CNS; 
involved in RNA transport and glycosylation 
DCTN1 dHMN VIIB





Widespread tissue distribution; RNA processing 
AR=autosomal recessive. BSCL2=Berardinelli-Seip congenital lipodystrophy type 2. CHN=congenital hypomyelinating neuropathy. 
CMT=Charcot–Marie–Tooth disease. DCTN1=dynactin. dHMN=distal hereditary motor neuronopathy. DI=dominant intermediate. DNM2=dynamin 
2. DSN=Déjèrine-Sottas neuropathy. EGR2=early-growth-response 2. FGD4=FGD1-related F-actin binding protein. FIG4=FIG4 homologue of 
Saccharomyces cerevisiae. GARS=glycil-tRNA synthetase. GDAP1=ganglioside-induced differentiation-associated protein 1. GJB1/Cx32=gap 
junction B1/connexin 32. HNPP=hereditary neuropathy with liability to pressure palsies. HSPB1/HSP27=heat shock 27-kDa protein 1. HSPB8/ 
HSP22=heat shock 22-kDa protein 8. IGHMBP2=immunoglobulin mu binding protein 2. KIAA1985/SH3TC2=SH3 domain and tetratricopeptide 
repeat domain 2. LMNA=lamin A/C nuclear envelope protein. MED25=mediator of RNA polymerase II transcription, subunit 25. MFN2=mitofusin 
2. MPZ=myelin protein zero. MTMR2=myotubularin-related protein 2. NDRG1=N-myc downstream-regulated gene 1. NEFL=neurofilament light 
chain. PMP22=peripheral myelin protein 22. PRPS1=phosphoribosylpyrophosphate synthetase 1. PRX=periaxin. RAB7=small GTPase late 
endosomal protein RAB7. SBF2/MTMR13=set-binding factor 2/myotubularin-related protein 13. SIMPLE/LITAF=small integral membrane protein 
of lysosome/late endosome; lipopolysaccharide-induced tumour necrosis factor-alpha factor. SMARD1=spinal muscular atrophy with respiratory 
distress 1. YARS=tyrosyl-tRNA synthetase.
Table 3: Mutated genes, associated phenotypes, and mutated protein locations and 
functions in CMT neuropathies (Adapted from Pareyson, D. 2009). 
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4.2 MPZ-RELATED CMTs 
Mutations in human MPZ gene result mainly in autosomal dominant neuropathies 
and are estimate to account for ~5% of all CMT cases. Currently, more than 200 
different MPZ mutations have been identified 
(http://www.molgen.ua.ac.be/CMTMutations/default.cfm), the majority of which 




















Figure 9: Mutations in the MPZ gene associated with inherited neuropathies.  
The numbering system for MPZ mutations includes the 29 amino acid leader peptide 
cleaved before insertion in the myelin sheath. Arrows represent frameshift mutations, 
lines represent nonsense mutation and letters represent aa change. Adhesive interface, 
4-fold interface and head-to-head interface refer to amino acid residues deemed 
essential for adhesion between adjacent myelin wraps (Sanmaneechai, O. 2015). 
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MPZ mutations can give rise to different phenotypes: an early-onset phenotype, 
with onset of the disease during the 1
st
 decade of life and characterized by very 
slow Motor Nerve Conduction Velocity (MNCV), a late-onset phenotype, with 
onset from the 2
nd
 decades of life and with a normal or minimally impaired 
MNCV, or a childhood-adolescent-onset, with motor and sensory symptoms 
during the 2
nd
 decades of life, and showing a slowly progressive course, with 
MNCV of intermediate range [123]. Collectively MPZ related mutations are 
usually referred as CMT1B. Also the way by which distinct MPZ mutations cause 
different phenotypes is different: mutations that cause infantile phenotype tend to 
disrupt the developmental process of myelination, while in cases of late-onset 
disease, myelin sheaths are formed but are slightly impaired and during aging this 
leads to an axonal degeneration that cause the neuropathy [121]. But why 
particular mutations cause so different phenotypes is not completely understood. 
Several MPZ mutations cause the mutated protein being retained in the ER instead 
of being transported to the myelin sheaths; in that way, the protein cannot be 
properly folded and lead to the activation of the Unfolded Protein Response 
(UPR). Other proposed pathomechanisms include the disruption of the 
intracellular adhesion properties [124] and misglycosylation of P0: in this latter 
case, there can be the loss of native glycosylation site, or the gain of a new 
glycosylation site [125, 126]. 
 
5. GLYCOSYLATION 
Glycosylation defines the reaction in which glycans are attached to proteins or 
lipids. Ten monosaccharides are used in the enzymatic process of glycosylation in 
mammals: fucose (Fuc), galactose (Gal), glucose (Glc), N-acetylgalactosamine 
(GalNAc), N-acetylglucosamine (GlcNAc), glucuronic acid (GlcA), iuduronic 
acid (IdoA), mannose (Man), sialic acid (SA) and xylose (Xyl) [127]. Glycan 
structures attached to proteins can be highly complex, due to multiple enzymatic 
site preferences, as well as the use of stereochemical α or β conjunctions. 
Structural diversity is mainly produced through the secretory pathway of cells; the 
glycosylation of proteins and lipids occurs in the ER and Golgi apparatus, with 
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most of the final processing occurring in the cis-, medial- and trans- Golgi 
compartment [128]. Protein glycosylation includes: 
N-glycosylation: consist of N-acetylglucosamine (GlcNAc) attached by a β1-
glycosidic linkage to the nitrogen atom of the amino group of Asn (N) at the 
consensus glycosylation motif Asn-X-Ser/Thr (in which X denotes any amino 
acid except for Pro). 
O-glycosylation: glycans are attached to the oxygen atom of the hydroxyl groups 
of Ser (S) or Thr (T) residues. O-glycans can be further subclassified on the basis 
of the initial sugar attached to the protein and the additional sugar structures 
added to the initial glycan. 
Glycosaminoglycans (frequently termed proteoglycans): represent a major class 
of glycoproteins that are defined by long glycosaminoglycan (GAG) chains 
attached to proteins through a tetrasaccharide core consisting of glucuronic acid 
(GlcA)–galactose (Gal)–Gal–xylose (Xyl); this carbohydrate core is attached to 
the hydroxyl group of Ser at Ser-Gly-X-Gly amino acid motifs. 
C-mannosylation: glycans are attached through C-C linkage to the C2 position of 
Trp in the sequence W–X–X–W (W indicates tryptophan; X is any amino acid). 
Glypiation: glycosylphosphatidylinositol (GPI)-anchored glycoproteins represent 
another major class of glycoconjugates. These glycoproteins are linked at the 
carboxyl terminus through a phosphodiester linkage to phosphoethanolamine 
attached to a trimannosyl-nonacetylated glucosamine (Man3-GlcN) core; the 
GlcN residue is linked to phosphatidylinositol, which is embedded in the cell 
membrane. 
The addiction of sugar to lipids formed glycolipids and, between this types of 
glycoconjugates, there are glycosphingolipids (Figure 10) [127-130].  
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Glycan moieties participate in multiple mechanisms: glycans associated with cell 
surface receptors and proteins directly modulate protein function and signalling, 
alter the dynamics of glycoprotein endocytosis and cell surface half-life by 
binding to multivalent lectins. Glycans structure is also fundamental for protein 
secretion and folding, contribute to quality control surveillance in the ER and 
mediate transit and selective protein targeting throughout the secretary pathway. 
In general, principal functions of glycans are the regulation of cytosolic and 
nuclear functions, immune surveillance, inflammatory reactions, autoimmunity, 




N-glycosylation comprises an assembly part and a processing part that are 
extended over three cellular compartments: the cytosol, the ER and the Golgi. The 
biosynthesis of the oligosaccharide initiates at the cytoplasmic side of the ER 
Figure 10: Major types of glycosylation in humans. 
Glycans can be covalently attached to proteins and lipids to form glycoconjugates. 
Glycoproteins consist of glycans and glycan chains linked to nitrogen and oxygen 
atoms of amino acid residues and are thus termed N-glycans and O-glycans, 
respectively. Other two major class of glycoproteins are proteoglycans and 
glycosylphosphatidylinositol (GPI)-anchored glycoproteins. Finally, 
glycosphingolipids are a class of glycoconjugates in which glycans are attached to 
cellular membrane lipids (Reily, C. 2019). 
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membrane with the transfer of N-acetylglucosamine (GlcNAc) phosphate from 
UDP-GlcNAc to membrane-bound carrier dolichyl monophosphate (Dol-P), 
forming GlcNAc-pyrophosphatedolichol (GlcNac-PP-Dol). Subsequently, one 
GlcNAc and five mannose (Man) residues are attached to this dolichol-linked 
monosaccharide; the lipid-linked Man5GlcNac2 is translocated across the ER 
membrane and is elongated at the lumen side by attachment of others four 
mannose and three glucose residues. The completed Glc3Man9GlcNAc2 
oligosaccharide is then transferred to specific asparagine residues of nascent 
proteins by the oligosaccharyl-transferase complex. The asparagine residues are 
specified by the consensus sequence N-X-S/T. The processing part of the N-
glycosylation starts in the ER, where glucose residues are removed as part of 
quality-control process; the structure than moves to the cis-Golgi, where the 
carbohydrate structures are further trimmed by a series of specific mannosidases 
before being transferred to medial-Golgi for maturation. It is within the medial- 
and trans-Golgi compartment that N-glycans are produced through the addition of 


















5.2 DEFECTS IN GLYCOSYLATION 
Genetic defects in glycosylation are often embryonic lethal, underlying the vital 
role of glycans [136, 137]. The disorders of glycosylation are classified in type I, 
when the disorder is caused by abnormalities in the formation of the 
oligosaccharide structure on the glycolipid precursor before the attachment to the 
Asp residue of the protein, or type II, if the defects are in the control of the N-
linked branching structure of the nascent glycoprotein [138]. As reported in 
Online Mendelian Inheritance in Man [OMIM] 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM), disorders of 
glycosylation include at least 21 disorders of protein N-glycosylation, 12 disorders 
of O-glycosylation and two disorders of the glycolipid synthesis pathway [139]. 
The mutated genes encode enzymes involved in glycosylation, either in the 
cytosol or in the secretory pathway. Other pathogenic mutations have been 
described that lead to a loss- or gain- of glycosylation of specific proteins encoded 
by the mutated genes, indicating the importance of glycosylation in human 
physiology [140-145]. 
In the Human Gene Mutation Database (HGMD) are reported a total of 20667 
pathogenic missense mutation affecting 1325 genes; between these genes, 577 
encodes proteins that are predicted to enter the ER and that are therefore likely to 
be exposed to the N-glycosylation machinery, while the remaining 748 genes 
encode proteins that are not predicted to enter the secretory pathway (the 
prediction if the proteins enter the secretory pathway or not is based on in silico 
identification of a signal peptide with a cleavage site or a signal anchor without a 
cleavage site, or the lack of signal peptide). Vogt and colleagues searched in 
HGMD for potential gain- or loss- of glycosylation missense mutations and, 
Figure 11: N-glycan biosynthesis in the secretory pathway. 
N-glycan synthesis is initiated in the ER by the transfer of a lipid-glycan precursor to 
an asparagine. After a quality-control checkpoint, the glycoprotein moves to the Golgi 
apparatus for additional trimming and further glycan modifications. The expression 
levels of glycosyltransferases, the accessibility of the glycoprotein glycosylation sites 
and the length of time during which the glycoprotein remains in the ER and Golgi 
apparatus all affect the final site-specific N-glycan composition (Reily, C. 2019). 
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among 577 genes encoding for proteins that migrate through the secretory 
pathway, they founded that up to 77 (~13,3%) may be subjected to potential gain 
of glycosylation (corresponding to ~1,4% of pathogenic missense mutations found 
in the 577 genes), indicating that this kind of mutations are more frequent that 
expected. Conversely, the loss of glycosylation sites was both less frequent and 
usually less severe, suggesting that the introduction of a new glycan might have a 
more disruptive effect on protein function than the loss of a glycan (Table 4) [98, 
146, 147]. 
 
P0 protein has a single glycosylation site in position 122 where there is present the 
sequence Asp122-X-Thr124; during post-translational modification, the 
carbohydrate is N-glycosidically linked to asparagine 122. For that reason, also 
the P0 protein is subjected to mutations that cause the gain- or the loss- of 
glycosylation. Different mutations in P0 protein causing loss of glycosylation 
have been reported: the substitution N
122





that lead to the loss of the glycosylation site, resulting in a late-onset neuropathy 
[148]. The very common mutation T
124
M, that lead to the loss of glycosylation 
site, is associated with a late-onset axonal neuropathy with sensory involvement 
[149]. Other mutations involving the threonine in position 124 include T
124
K 
Table 4: Predicted gain and losses of consensus N-glycosylation site associated with 
missense mutations in the HGMD. A total of 20667 pathogenic missense mutations 
affecting 1325 genes have been logged in the HGMD. Of these genes, 577 encode 
proteins that are predicted to be exposed to the N-glycosylation machinery; the 
remaining 748 genes encode proteins that are not predicted to enter the secretory 
pathway. The numbers of documented pathogenic missense mutations, including those 
that lead to a potential gain or loss of N-glycosylation (based on the creation or 
removal of a consensus site for N-glycosylation), with the corresponding total number 
of possible missense mutations (created in silico) for each of these three groups are 




A [151] have been reported and both of them correspond to 
unglycosylated proteins. Interestingly, also mutations causing gain of 
glycosylation have been reported: the mutation D
61
N resulted in a 
hyperglycosylated form of P0, causing an early-onset demyelinating neuropathy 
[126, 152]. Analyzing the Inherited Peripheral Nervous System Mutation 







N [155] that potentially introduce a new glycosylation sequon, 
even if the gain of glycosylation was not further studied. Also for P0 mutations, 
most mutations causing a loss of glycosylation are associated with a late-onset 
phenotype, whereas the majority of mutations associated with a gain of 
glycosylation, cause a severe, early-onset neuropathy, supporting the idea that 
loose a glycosylation site is less important than acquiring one. 
 
6. CLINICAL CASES OF PATIENTS WITH D61N MUTATION 
Literature reports two distinct patients affected by CMT1B that present the amino 
acidic substitution D
61
N that introduces a new glycosylation site in the P0 
protein [126, 152]. 
Case 1 [126] 
The patient is a 46-year-old Italian woman, with no family history of 
neuromuscular disease. She did not begin walking until two years of age. In the 
childhood, she fell frequently and was severely impaired in running and climbing. 
During her second decade she developed prominent wasting and weakness of both 
hands and legs. Because of severe pes equinovarus she underwent surgery at 24 
years of age. On neurological examination she presented bilateral claw hand 
deformity and foot drop, with moderate proximal wasting and weakness (4/5 
MRC) of the lower limbs. Vibration sense was decreased at the lower limbs. Deep 
tendon reflexes were diffusely absent and a stepping gait was observed. Both 
motor and sensory action potentials were unrecordable. A sural nerve biopsy, 
performed when she was 20 years old, showed a severe loss of myelinated fibers 




Case 2 [152] 
A boy aged 2 years and 11 months was evaluated for gross motor delay and 
generalized hypotonia. No family history of neuromuscular disease was reported. 
He sat independently at age 8 months, but was unable to stand with support at 12 
months of age. He began crawling at age 15 months, and walked independently at 
age 2 years and 3 months. He was alert and bright, but his face appeared 
myopathic. Physical examination revealed a mildly high-arched palate, but neither 
thenar plus hypothenar atrophy nor pes cavus. A cranial nerve examination 
revealed normal ocular movements and pupillary responses to light. Mild facial 
muscle weakness was evident. Tongue fasciculations were absent. He was 
hypotonic, but his muscle strength was only mildly reduced in the four 
extremities. Hyperextension was observed in the finger, wrist, and knee joints. His 
muscle bulk was normal. Deep tendon reflexes were absent at the biceps, triceps, 
patella, and ankles. No sensory disturbance was evident. He was able to stand up 
from a supine position using a modified Gowers maneuver. His gait, with bilateral 
genu recurvatum, was wide-based and ataxic. Cranial magnetic resonance imaging 
indicated no intracranial abnormalities. A nerve conduction study revealed very 
prolonged distal latencies, markedly reduced motor conduction velocities (3.0-4.0 
m/second), and the temporal dispersion of compound muscle action potentials 
Figure 12: Images of the sural nerve biopsy from the patient of the case 1. 
Sural nerve biopsy of the patient carrying the MPZ mutation D61N. 
A) Toluidine Blue, 25X. 
B) Toluidine Blue, 100X. A severe loss of myelinated fibers can be observed, with 
some residual fibers containing myelin outfoldings (thin arrow) (Prada, V. 2012). 
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from his upper and lower extremities. To evoke motor nerve responses, electrical 
stimuli greater than 50 mA were necessary. Sensory responses were not evoked. 
Magnetic resonance imaging of the lumbar plexus demonstrated no enlarged 
nerve roots. A sural nerve biopsy revealed a severe loss of large myelinated fibers 
in all fascicles. Well-organized onion-bulb formations were not evident. No 
inflammatory infiltrates, edema, or storage materials were observed. 
Intramuscular nerves rarely included large myelinated fibers. A teased fiber 
analysis demonstrated thin, myelinated segments and tomacula-like structures. 
Electron microscopic examination revealed occasional onion- bulb formations 
consisting of multilayered empty basal lamina. Occasional fibers with thin or 
abnormally compacted myelin were also observed. Unmyelinated fibers were well 








Figure 13: Images of the sural nerve biopsy from the patient of the case 2. 
A) Epoxy-embedded and toluidine blue-stained semithin section of the sural nerve 
reveals the endoneurium, including nonmyelinated (arrows), hypomyelinated, and 
hypermyelinated (double arrows) fibers. Bar, 20 mm. 
B) Teased fiber analysis demonstrates thin, myelinated segments and tomacula- like 
structures. A lack of myelination is evident in the nerves. 
C) Electron microscopy reveals an absence of myelin and onion-bulb formations 
consisting of multilayered empty basal lamina. Bar, 2 mm. 
D) Electron microscopy indicates abnormally compacted myelin. Bar, 2 mm 
(Yonekawa, T. 2013). 
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AIM OF THE PROJECT 
 
The aim of this project was to investigate how peripheral myelination is affected 
by P0 misglycosylation. We used two different strategies: 
1) Characterize, in different in vitro models, the effects of P0 mutants causing 
gain- or loss- of glycosylation. In particular, we evaluated if the mutations 
predicted to cause a gain- or loss- of glycosylation corresponded to hyper or 
unglycosylated P0 mutants and if this mutations were able to interfere with the 
sorting to the cell membrane and with the adhesive function of P0. Indeed, since a 
group of molecules, defined imino-sugars, might complement hyperglycosylation, 
we decided to evaluate if NB-DNJ (Miglustat), a molecule belonging to this group 
of compound, was able to rescue in vitro the effects of one mutation causing 
hyperglycosylation. 
2) Establish a murine model of MPZ
D61N 
mutation to evaluate in vivo the effects of 
hyperglycosylation. We evaluated if the "knock in" mouse model carrying the 
amino acidic substitution D
61
N developed a demyelinating neuropathy, 
providing a model of CMT1B due to hyperglycosylation of P0; finally, we 
obtained from WT and MPZ
D61N 
mice a model of ex-vivo myelination to dissect 
axonal-glia interplay and to test imino-sugars as potential therapies for 
hyperglycosylation. 
The importance of this study is due to the fact that, while peripheral myelin is 
largely composed by glycoproteins, misglycosylation has never been investigated 
as a cause of peripheral neuropathies. Misglycosylation is a novel 
pathomechanism that may occur in P0 related neuropathies which deserves a 
complete characterization. To our knowledge the MPZ
D61N
 mouse model is the 
first transgenic mouse expressing a gain-of-glycosylation mutant, with relevant 
implications for other diseases caused by hyperglycosylation such as rare 
mutations causing Cystic Fibrosis, different immunodeficiencies [146] and 




MATERIALS AND METHODS 
 
Plasmids generation and site-directed mutagenesis 
The full-length human cDNA of wild-type MPZ gene has been cloned into the 
expression vector for mammalian cells pEGFP–N1 (Figure 1) as previously 
described [125]. 
 
Through site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis 
Kit, Stratagene), different plasmids coding for all the mutations in fusion with 
EGFP vector (pEGFP from Clonetech) have been generated, using specific 
primers containing the nucleotide changes (Table 1), according to manufacturer’s 
protocol. The mutated cDNAs were amplified by PCR using primers containing 
restriction enzyme sites for EcoRI and BamHI, and then fused in-frame into the 
expression vectors for mammalian cells pEGFP–N1 (Clontech, Mountain View). 
 
 
Figure 1: Schematic representation of the pEGFP-N1 expression vector with detail of 
the multiple Cloning Site (MCS). P0wt and selected mutations were cloned using 






HeLa cell and Schwannoma RT4-D6P2T lines were maintained in Dulbecco’s 
Modified Eagle’s Medium (Gibco, Invitrogen) supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine and 1% penicillin/ streptomycin at 37°C, in a 
humidified incubator with 5% CO2. 
 
Transient transfection and protein localization 
Table 1: List of mutations that have been cloned in pEGFP-N1 vector; the position of 
the mutation and sequence of the primers are reported. 
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HeLa and Schwannoma cells were transiently transfected with each mutant-EGFP 
construct, by single transfection using Lipofectamine 2000 according to 
manufacturer’s protocol (Invitrogen). 
To study the expression of P0wt and its mutations on the cell surface, HeLa and 
Schwannoma cells were transfected with both P0wt and mutated P0 linked to 
EGFP, allowed to grow for 24 hours in a chamber slide (Nalge Nunc 
International), washed with PBS and fixed in 4% paraformaldehyde for 10 
minutes, washed and mounted.  
 
Biotinylation and endocytic assay 
Transiently transfected cells (P0wt-EGFP and mutants-EGFP) were subjected to 
two washings with cold PBS, containing calcium and magnesium at a 
concentration of 1 mM of MgCl2 and 0.1 mM of CaCl2 (PBS Ca/Mg) and then 
were treated with sulfosuccinimide-NHS-biotin (1.5 mg/ml; Pierce, Rockford) in 
PBS Ca/Mg at 4°C for 1 h. Biotinylating reagents were removed by washing with 
PBS Ca/Mg  twice and by further quenching with 100 mM glycine for 30 min. 
Cells were then lysed with RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 
mM EDTA, 0,1% SDS, 1% Triton X-100, 0,5% sodium deoxycholate and 
Protease Inhibitor (4693132001, Sigma)). After a centrifuge of 45 min at 4°C, 
supernatants were incubated with streptavidin magnetic beads (2 mg of beads/500 
ml of supernatant; New England Biolabs) for 1 h at RT. Beads were washed three 
times with RIPA buffer, and adsorbed proteins were eluted with 100 μl of 
Laemmli loading buffer for 5 min at 95°C. Equal amounts of proteins were 
separated by SDS-PAGE and immunoblotted with anti-EGFP antibody and with 
HRP-conjugated secondary antibody. Immunoreactive bands were visualized by 
ECL on hypersensitive ECL film (Amersham, GE Healthcare). Trafficking was 
evaluated also with endocytic assay [157]: after the treatment with 
sulfosuccinimido-NHS-biotin, cells were incubated at 37°C for 5 min to induce 
endocytosis and then tranfered at 4°C to stop the reaction. With the addition of L-
glutathione (GSH solution) (50 mM GSH, 75 mM NaCl, 1 mM MgCl2, 0.1 mM 
CaCl2, 80 mM NaOH, 10% FBS) at 4°C for 15 min (repeated three times) 
disulfide bond in biotin covalently attached to plasma membrane proteins have 
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been reduced. Following those treatments, cells have been lysed, biotinylated 
proteins have been isolated by streptavidin, eluted into SDS sample buffer and 
separated by SDS-PAGE. 
 
Adhesion test 
After 24h from transient transfection, HeLa cells were washed with PBS and 
incubated with Cell Dissociation Buffer (Invitrogen, San Giuliano Milanese, MI, 
Italy), for 3 min at RT, counted in Bürker chambers and resuspended to a final 
concentration of 1.5x10
6
 cells/ml in DMEM containing 10% FBS and 25 mM of 
Hepes (Sigma) to maintain the cellular pH. By three passages through an 18-
gauge syringe, we obtained a single cell suspension. Suspensions, containing a 
minimum of 95% single cells, were allowed to aggregate at 37°C with gentle 
rocking at 5 rpm. After 3 h, the tubes were gently inverted and aliquots of 10 μl 
were removed, put on a microscope slide without using fixatives and immediately 
examined under the microscope (Olympus AX60). From each slide, 30 frames, 
randomly selected at 20X magnification, were digitalized and stored, using the 
Pro Plus Imaging System (Immagini e Computer). The area of cellular aggregates 
(>4 cells) were measured with Pro Plus Imaging System (Immagini e Computer) 
and the average area of aggregates formed by HeLa cells transfected with each 
mutant was calculated and normalized to the average area of aggregates produced 
by cells expressing P0wt.  
 
Animals 
All experiments involving animals were performed in accordance with Italian 
national regulations and in accord with experimental protocols approved by the 
San Raffaele Scientific Institute Animal Care and Use Committees. 
MPZ
D61N
 mice were generated by Core Facilities for Conditional Mutagenesis 
(CFCM) using the CRISPR/Cas9 technology. The CRISPR/Cas9 system used for 
gene editing takes advantage of a guide RNA that detects the specific sequence in 
the genome and the Cas9 enzyme that binds to the single guide RNA and cleaves 
the DNA at the target site. In the case where a specific mutation is to be 
introduced at the cut site, a repair template DNA carrying the mutation is also 
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needed. The CRISPR/Cas9 components can be introduced into one-cell staged 
mouse embryo to generate offspring that contains the desired knock-in mutation. 
The process involves four steps: designing of CRISPR targets; synthesis and 
purification of RNA and DNA components; isolation of one-cell staged mouse 
embryos, micro-injection of CRISPR/Cas9 components and transfer of injected 
embryos into pseudopregnant mice; genotyping of offspring to identify the 
mutation [158]. The generation of the MPZ
D61N
 mouse model was performed in 
collaboration with Sigma-Aldrich that designed molecular component. 
The donor oligo contains: 
1. G>A snp conversion that introduce the desired mutation; 
2. A>G snp conversion that is necessary to prevent gRNA binding and re-
cleavage possibility; 
3. A>T snp conversion that eliminates the DdeI restriction enzyme site. 
For genotyping, genomic DNA was extracted from tail biopsies. All PCR 
products were stained with SYBR Safe DNA Gel Stain (Invitrogen), run in 3% 
agarose gels and detected with UVP GelDOC-It Imaging System.  
D61N PCR primers: 
D61N sense: 5’ TGCTCTCTCCAGCCCTGG 3’ 
D61N antisense: 5’ GGAGCCATCCTTCCAGCGA 3’ 
PCR program: 
95°C 10’ 
 95°C 30’’ 
 60°C 30’’           30 cycles 





Expected band size: 
Before digestion: 491 bp 
After digestion: WT: 110, 168, 213 bp 
D61N/+: 110, 168, 213, 323 bp 
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Morphological and morphometric analysis 
Sciatic nerves were freshly dissected, fixed in 2% glutaraldehyde in phosphate 
buffer, osmicated in 1% OsO4, alcohol dehydrated, infiltrated with propylene 
oxide and embedded in Epon. Transverse semithin sections and ultrathin sections 
were cut with an Ultracut microtome. Semithin sections were stained with 
toluidine blue and acquired with a Leica DM5000 microscope equipped with a 
DFC480 digital camera, whereas ultrathin sections were stained with lead citrate 
and photographed with a Zeiss (Oberkochen, Germany) EM10 electron 
microscope. g-ratio (axon diameter/fiber diameter) was measured on semithin 
sections using ImageJ software; four-six images per nerve were acquired with a 
100X objective; ~800–2000 fibers per condition were measured. The proportion 





 and 8 control mice were analyzed at 1 month and 3 months old. 
Electrophysiological tests were performed using an EMG system (NeuroMep 
Micro, Neurosoft, Russia). Mice were anesthetized with trichloroethanol, 0,3 
mg/g of body weight, and placed under a heating lamp to maintain a constant 
body temperature. Monopolar needle electrodes were inserted subcutaneously to 
stimulate the tibial nerve at the ankle and, subsequently, the sciatic nerve at the 
sciatic notch; the cathode was placed close to the nerve and the anode was 
inserted proximally to the cathode. The stimulation consisted of single 100 μs, 
1Hz supramaximal pulses. The muscular response was recorded by inserting the 
active electrode into muscles in the middle of the paw and the reference electrode 
in the skin between the first and second digit. NCV (m/s), peak-to-peak cMAP 
amplitude (mV) and F-Wave Latency (FWL) (ms) were measured. FWL 
measurement was obtained stimulating the tibial nerve at the ankle and recording 
the responses in the paw muscles, using the same pair of needle electrodes used 




Tremor was estimated visually on a + to ++++ scale. 
Rotarod test 
Motor ability was assessed using the accelerating Rotarod (Ugo Basile, Comerio, 
Italy). Groups of 3 months old transgenic and control littermates were tested in 
two sessions of three trials each per day (6 h rest between the two daily sessions) 
for 3 consecutive days. During the test, the rod accelerated from 4 to 40 rotations 
per minute, and the time that the animal remained on the rod (maximum 900 s) 
was measured. 
Grip strength test 
The grip strength test is a simple non-invasive method designed to evaluate mouse 
muscle force and hind limb strength. Grip strength test was performed on a group 
of 9 MPZ
D61N/+
 and 10 WT mice at 3 months of age using a grip strength meter 
(Grip-Strength Meter, 47200, Ugo Basile, Italy) to determine hind limbs muscle 
strength. The grip strength meter was arranged horizontally on the table. While 
holding the tails, the mice were lowered towards the grip strength meter to enable 
to grasp the T-shaped bar with the hindpaws. After grasping the bar, the mice 
were pulled backwards till the grasp was released. The test was repeated six 
consecutive time. For each session the average value of the peak force (in gf) was 
calculated [160]. 
 
TaqMan quantitative PCR analysis 
Total RNA was extracted with Trizol (Roche Diagnostic GmbH, Germany) and 
retrotranscribed as previously described [124]. TaqMan assays were performed 
following manufacturer’s instructions (TaqMan, PE Applied Biosystems 
Instruments) on an ABI PRISM 7700 sequence detection system (Applied 
Biosystems Instruments). Normalization was performed using 18S rRNA as 
reference gene. Target and reference genes PCR amplification were performed in 
separate tubes with Assay on Demand (Applied Biosystems Instruments): 18S 
assay, Hs99999901_s1; Ddit3/Chop assay, Mm00492097_m1; Xbp-1s assay, 
Mm03464496_m1; Hspa5/BiP assay, Mm00517691_m1; MPZ assay, 




Western blot analysis 
Sciatic nerves were dissected and frozen in liquid nitrogen. Frozen nerves were 
pulverized on dry ice and proteins were extracted in denaturing lysis buffer (Tris-
HCl 50 mM pH 7.5, NaCl 150 mM, EDTA 10 mM, 2% SDS) containing protease 
inhibitor cocktail (PIC 100X, Roche) and phosphatase inhibitors (Roche). Total 
protein concentration was determined by BCA assay (Pierce) following 
manufacturer’s instructions. Equal amounts of proteins were separated by SDS-
PAGE (Biorad) and gels were transferred onto nitrocellulose membrane (GE 
Healthcare). Membranes were blocked with 5% milk (milk powder/ 1X PBS-
Tween 0.1%) or 5% BSA (BSA powder/ 1X PBS-Tween 0.1%) and incubated 
with primary antibodies diluted in 1% milk or 1% BSA/ 1X PBS-Tween 0.1% at 
4°C overnight. HRP-conjugated antibodies were diluted in 1% milk or 1% BSA/ 
1X PBS-Tween 0.1% and incubated 1 h at RT. Signals were detected by ECL 
method. Densitometric analysis was performed with NIH-Image-J software. 
 
PNGaseF treatment 
For the digestion with PNGaseF, an amidase that cleaves N-glycans, proteins 
were extracted from sciatic nerves or from Hela cells as previous described for the 
western blot analysis, but using the RIPA buffer, digested for 1 h at 37°C with 
PNGaseF, according to manufacturer’s protocol (NEB), separated by SDS-PAGE 
and immunoblotted. 
 
Teased fibers preparation 
Sciatic nerves were freshly dissected, fixed in 2% glutaraldehyde in phosphate 
buffer, osmicated in 1% OsO4 in triethyl phosphate and placed in glycerol. Single 
fibers were separated with fine needles, placed on slides and analyzed with a light 
microscope (Leica DM5000). 
 
Myelinating Dorsal Root Ganglia (DRG) explant cultures 
DRG explants were isolated from E13.5 WT and D61N/+ embryos, seeded on rat 
collagen I-coated coverslip and maintained in cultures as previously described 
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[33]. Myelination was induced by supplementing media with 50 μg/ml ascorbic 
acid (Sigma-Aldrich) for 14 days. Culture medium was refreshed every two days. 
Samples were fixed and prepared for immunofluorescence. 
 
Immunohistochemistry and analysis of myelination 
Schwann cell/DRG neuron co-cultures were fixed for 15 min in 4% 
paraformaldehyde, permeabilized for 3 min in ice-cold methanol, blocked for 1 h 
with 1% BSA + 10% NGS in PBS, and incubated at 4°C overnight with primary 
antibody. After washing, the coverslips were incubated 1 h at room temperature in 
the dark with secondary antibody, washed, incubated for 5 min in the dark with 
Hoechst solution for nuclei staining, washed and mounted with Vectashield. To 
quantify the amount of myelin, 8 non-overlapping images per DRG were acquired 
with a Leica DM5000 microscope (10X and 20X objectives) equipped with a 
Leica DFC480 digital camera and the number of MBP-positive myelinated fibers 
were counted. The percentage of MBP-positive fibers showing myelin 
abnormalities among the total number of MBP-positive fibers was indicated. At 
least 3 independent dissections were performed. 
 
Antibodies 
For western blot the following primary antibodies were used: chicken anti-myelin 
protein zero (P0) (PZO; Aves); mouse anti-myelin basic protein (MAB 382; 
Chemicon); rabbit anti-PMP22 (AB211052; ABCAM); rabbit anti-eIF2α (D7D3) 
XP (5324; Cell Signaling); rabbit anti-phospho-eIF2α (Ser51) (D9G8) XP (3398; 
Cell Signaling); rabbit anti-p44/42 (ERK1/2) (9102; Cell Signaling); rabbit anti-
phospho-p44/42 (Thr202/Tyr204) (4370; Cell Signaling); rabbit anti-AKT (9272; 
Cell Signaling); rabbit anti-phospho-AKT (Ser473) (9271; Cell Signaling); rabbit 
anti-GRP78 (BiP) (NB 300520; Novus Biological); mouse anti-β-tubulin (T4026; 
Sigma); rabbit anti-Calnexin (C4731; Sigma); mouse anti-GFP tag (GF28R) 
(MA515256; Thermo Fisher). 
For immunofluorescence the following primary antibody was used: rat anti-MBP. 
Secondary antibodies included donkey anti chicken-HRP (AB 16349; ABCAM); 
horseradish peroxidase (HRP)-conjugated goat anti rabbit (P0448; Dako); anti-
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mouse IgG Peroxidase (A3682; Sigma Aldrich) and Mouse IgG HRP-linked 
whole Ab (10196124; Fisher Scientific). For immunofluorescence, secondary 
antibody included Cy3-conjugated goat anti-rat (112166062; Jackson 
ImmunoResearch), Alexa Fluor 546 goat anti-mouse IgG (A11030; Thermo 
Fisher). For immuno-EM the following antibodies were used: monoclonal anti-P0 
protein were donated by Dr. JJ Archelos (Karl Franzen universität, Graz, Austria); 
secondary goat anti-mouse conjugated to 6-, 12-, or 18- nm gold particles were 





In silico prediction of gain/loss of N- and O-linkage sites in MPZ gene 
Protein misglycosylation following a missense mutation denotes the introduction 
of a new glycosylation site or the removal of a constitutive one; this mechanism is 
more frequent than expected [146, 147] and it is has been described also for MPZ 
mutation [98, 126, 149, 152]. The Mutation Database of Inherited Peripheral 
Neuropathies (http://www.molgen.ua.ac.be/CMTMutations/default.cfm) shows 
126 mutations in the MPZ gene. If we consider the missense mutations affecting 
amino acids within P0ECD, the reported mutations are 84. With the help of two 
free, dedicated softwares, NetNGlyc 1.0 Server and NetOGlyc 3.1 Server [161], 
we have introduced in the MPZ sequence all the amino acid changes reported in 
the database and identified four more MPZ mutations, all in the extracellular 
domain, potentially able to produce hyperglycosylated forms of P0: D61N [126]; 
D109N [153]; D118N [154] and K138N [155]. The N-glycosylation efficiency of 
a N-X-S/T sequon depends on multiple factors, including the proximity to the C-
terminal of the protein and the presence of particular amino acids in close 
proximity to the glycosylation site, being some of them favorable to 
glycosylation, whereas others render the modification unlikely [162]. The four 
mutations already listed are all far from the C-terminal and none of them presents 
unfavorable amino acids. Interestingly, the new glycosylation sequence of 
K138N, is preceded by a glycine which render effective glycosylation a likely 
event [162]. However, the D118N mutation is very close to the wild type acceptor 
sequon, which is in position 122. The existence of a minimal distance between 
consecutive N-glycosylation sequences has been debated, but theoretically N-
glycosylation may occur also for overlapping glycosites [163]. Differently, none 
of the described MPZ mutations reached a score over the threshold of NetOGlyc 
3.1 Server, meaning that a gain-of-O-glycosylation is unlikely. The analysis of the 
database highlighted also three MPZ mutations preventing the native 
glycosylation acceptor site: N122S [148], T124M [149], T124K [150]. Our group 
has described a fourth mutation, T124A [151], also affecting the unique P0 
glycosylation site. The percentage of predicted misglycosylated P0 mutants is 
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6,3% if considering all mutations and 9,5% if restricting the analysis to the 
missense substitutions within P0ECD, thus representing a potentially relevant 
pathomecanism.  
 
Generation of MPZ mutations in vitro 
Through site-directed mutagenesis, we generated different constructs coding 
EGFP-tagged versions of all the mutant proteins and expressed them in 
Schwannoma cell line. Western blot analysis showed that the predicted 
hyperglycosylated mutants displayed a molecular weight (MW) always higher 
than that of P0wt, even if it varied from the highest MW of K138N to the lowest 
MW of D118N (Figure 1A), whereas the predicted hypoglycosylated proteins 




Next, to test whether the higher MW of D61N, D109N, D118N and K138N was 
due to extra glycans, we treated protein extracts from transfected cells with 
PNGaseF, an amidase that cleaves N-glycans. This assay showed that after 
treatment, the MW of all mutant proteins decreased to the same level of P0wt 
treated with the same amidase, thus demonstrating that the higher MW of these 
mutant proteins was due to additional oligosaccharides. Conversely, none of the 
Figure 1: MPZ mutation in vitro: differences in molecular weight 
Western blot of Schwannoma cells transiently transfected with the different MPZ 
plasmids: 
A) the MW of fusion proteins predicted to be hyperglycosylated is higher compared to 
the MW of P0wt, varying from the highest MW of K138N to the lowest MW of 
D118N. 
B) the MW of proteins predicted to be hypoglycosylated appears to be lower than the 
MW of P0wt. 
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P0 variants predicted to be non-glycosylated were sensitive to PNGaseF, thus 
confirming that they lack glycans (Figure 2A). To further demonstrate the 
hyperglycosylation and that the increase of the MW was really due to the second 
oligosaccharide, we generated constructs carrying each predicted gain-of-
glycosylation MPZ mutation together with the N122A mutation, to produce P0 
variants with the unique novel glycosylation site but without the wild type N-
sequon N122. Again, all of these mutant proteins presented a higher MW 
compared to the P0wt and all these proteins were sensitive to PNGaseF treatment, 
further proving that they all have a second glycosylation site (Figure 2B, C, D).  
 
 
Evaluation of protein localization and intracellular adhesion of MPZ 
mutations in vitro 
To verify whether P0 misglycosylation was altering P0 trafficking and 
localization, we transfected different cell lines (HeLa and Schwannoma RT4-
D6P2T) with EGFP-tagged mutant proteins. Immunofluorescence analysis 
Figure 2: Treatment with PNGaseF of MPZ mutations in vitro  
Schwannoma cells have been transiently transfected with the different MPZ plasmids: 
A-D) Western blot of hyperglycosylated and hypoglycosylated proteins treated with 
PNGaseF; all the predicted hyperglycosylated proteins were sensitive to PNGaseF, 
while the predicted hypoglycosylated were not. Concerning the hyperglycosylated 
mutations, we studied also the double mutants carrying the additional N122A 
mutation that eliminates the constitutive glycosylation site. All double mutants were 
sensitive to PNGaseF, thus proving that the novel glycosylation sites are glycosylated. 
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showed that whereas P0wt reached the cell membrane, the hyperglycosylated 
proteins D61N, D109N and K138N were partially retained intracellularly (Figure 
3A). Conversely, the D118N hyperglycosylated mutant and all the 
hypoglycosylated mutant proteins normally reached the plasma membrane (Figure 
3A and data not shown). 
To further investigate the trafficking of the hyperglycosylated mutant proteins, we 
performed also a biotinylation/endocytic assay [157]; this assay allows to 
understand if a protein reaches the plasma membrane and if it is recycled by the 
endosomes, indicating a rapid internalization of the protein. This analysis 
suggested that all the hyperglycosylated proteins were biotinylated, consistent 
with membrane protein insertion; however, mutant variants are more endocytosed, 
supporting the hypothesis of an increased instability compared with wild type 






In myelin, P0 protein has an essential role in the adhesion of adjacent membrane 
wraps, through the formation of functional tetramers. To test whether the 
misglycosylating mutations interfered with this function, we performed an 
aggregation assay in transiently transfected HeLa cells [125]. The size of 
aggregates formed by cells expressing P0wt protein were indicated as 100% and 
were used as reference value; cells expressing hyperglycosylated P0 proteins 
formed aggregates which were smaller as compared to P0wt: the size of D61N 
aggregates were 67%, those of D109N were 54%, those of D118N were 70% and 
those of K138N were 67%; these results supported the hypothesis that 
hyperglycosylated variants impair the adhesion property (Figure 4A). Instead, 
cells expressing hypoglycosylated P0 proteins formed aggregates similar to those 
formed by the cells expressing P0wt, with the exception of T124K that formed 
smaller aggregates (the size was 59% compared to the size of P0wt aggregates) 
(Figure 4B). In both the adhesion test were measured also the aggregates formed 






Figure 3: Protein localization in vitro 
A) Confocal microscopy of Hela cells transiently transfected with EGFP-tagged 
hyperglycosylated proteins; the mutant proteins D61N, D109N and K138N are 
partially retained intracellularly, whereas D118N appears to be normally trafficked. 
B) Biotinylation-endocytic assay: +-- indicate proteins that are only biotinylated, +-+ 
proteins that are biotinylated and treated with GSH solution to reduce disulfide bonds, 
+++ proteins that are biotinylated, in which endocytosis has been induced and the 
disulfide bond are reduced with GSH solution; the WB showed that the signal 
produced by mutated proteins in which the endocytosis has been induced (+++ bands) 
is higher than the signal produced by P0wt subjected to the same treatment, indicating 
that these proteins are more endocytosed. As expected, the empty vector didn't reach 





Altogether these data indicate that the hyperglycosylated mutations, but not the 
hypoglycosylated ones, interfered with protein localization and protein adhesion 
properties, confirming the general rule that gain-of-glycosylation is more 
disruptive compared with loss-of-glycosylation [146, 147] and suggesting to 




 mice, a model for the hyperglycosylation 
To evaluate in vivo the effects of hyperglycosylation, we established a transgenic 
mouse model for the Mpz
D61N
 mutation using the genome-editing tool CRISPR-
associated protein 9 (Cas9) nuclease. The CRISPR/Cas9 system in fact allows the 
precise editing of the mouse genome to introduce specific nucleotide changes 
[164], thus perfectly mimicking human disease mutations. In particular, for the 
Figure 4: Adhesion properties of mutated proteins 
A) Adhesion test on HeLa cells transfected with P0wt and the hyperglycosylated 
proteins. The graph shows the area of aggregates formed by the cells transfected with 
the different proteins: the majority of the hyperglycosylated proteins formed smaller 
aggregates compared to the aggregates formed by P0wt, indicating a decrease in 
adhesion ability (One-way ANOVA corrected for multiple comparison using 
statistical Tukey test). 
B) Adhesion test on HeLa cells transfected with P0wt and hypoglycosylated proteins; 
all the hypoglycosylated protein, except for the T124K, formed aggregates similar to 
that formed by the P0wt (One-way ANOVA corrected for multiple comparison using 
statistical Tukey test). 
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generation of the Mpz
D61N 
model, three different snp conversions were introduced: 
a G>A conversion (position 181) that introduced the desired D to N amino acidic 
change, a A>G conversion (position 168) that prevent gRNA binding and 
recleavage possibility and a A>T conversion (position 177) that eliminates the 
DdeI restriction enzyme site (Figure 5A); the latter conversion allowed us to 
discriminate between WT and mutant mice (Figure 5B). The A>G and A>T 
conversions were designed not to cause any amino acidic change, so that the only 
difference in amino acid sequence as compared to P0wt is the D to N in position 
61. To confirm that the mutant P0D61N protein is hyperglycosylated in vivo, we 
performed a PNGaseF assay on protein extracts from sciatic nerves of WT and 
mutant Mpz
D61N/+ 
mice at one month. The untreated WT lanes are characterized by 
a single band (29kDa), while the mutant extracts present two distinct bands, one 
corresponding to the WT and a second one with a higher MW. After PNGaseF 
treatment, the MW of P0 in the Mpz
D61N/+
 extracts collapses to a single lower band 
of the same MW as the WT, demonstrating that the increased MW of the upper 






 mice present severe impairment in motor capacity and 
neurophysiology 
Mice heterozygous for Mpz variant D61N (Mpz
D61N/+
) were viable, bred normally 
and pups were born with the expected mendelian ratio and were initially 
indistinguishable from WT littermates. Mpz
D61N/+
 mice started manifesting a 
tremoring phenotype around postnatal day 15 (P15). The tremor was visually 
estimated on a + to ++++ scale and it worsened with ageing, but without 
impairing life expectancy (Figure 6A).  
To test whether this tremor would affect motor ability we evaluated the latency to 
fall on the accelerating Rotarod [124] in mice at three month of age. The mean 
latency to fall off the rotarod over the 3-day trial period was 184,7 ± 14,21 s for 
Mpz
D61N/+
 mice, as compared to 329,7 ± 23,24 s for WT (P value < 0,0001) 
(Figure 6B). We performed another behavioral test to evaluate the force and hind 
limb strength of Mpz
D61N/+
 mice compared to WT mice at three months of age: the 
grip strength test. We measured the maximal force produced during the pull in six 
different trials and we obtained that the mean force in WT animals was 97,19 ± 
4,4 gr, while in Mpz
D61N/+
 mice the mean force was 82,68 ± 4,1 gr (P value 
Figure 5: Mouse model generation  
A) Comparison between P0 protein sequence before and after the introduction of snp 
conversion to generate the Mpz
D61N 
model: in blue the snp conversion to prevent 
gRNA binding and recleavage possibility, in green the snp conversion that eliminates 
the DdeI restriction enzyme site and in yellow the snp conversion that introduces the 
desired mutation. 
B) PCR products before and after digestion with DdeI enzyme: before digestion the 
PCR product is 491 bp; after digestion, there are three bands of 110 bp, 168 bp and 
213 bp in wild-type animals, while, in mutant mice, there are two bands of 168 bp and 
323 bp, so that the Mpz
D61N/+
 mice display a total of 4 bands. 
C) Proteins extracted from sciatic nerves of WT and Mpz
D61N/+
 animals were treated 
with PNGaseF; before PNGase digestion, P0wt runs as a single band while P0D61N/+ 
extract shows a double band. After treatment with PNGaseF, the MW of P0 in 
Mpz
D61N/+
 samples decreases to a single band of the same MW of control proteins 
treated with the same enzyme. 
 55 
0,0246) (Figure 6C). With this two tests, we demonstrated that Mpz
D61N/+
 mice 




Next, we performed electrophysiological analysis on mutant and control animals 
at one and three months of age; we evaluated the sciatic nerve motor conduction 
velocity (MCV), the F-wave latency, the distal and proximal latency and the distal 
and proximal amplitude. At one month of age, all the parameters were 
significantly altered in Mpz
D61N/+
 as compared to WT. In particular, MCV was 
significantly lower (12,05 ± 1,22 m/s) as compared to controls (33,02 ± 1,622 
m/s), with prolonged latencies and a severe decrease of cMAPs (Figure 7).  
Figure 6: Mpz
D61N/+ 
mice present motor impairment 
A) Table describing the features of WT and Mpz
D61N/+
 mice at different time points; 
the scale of tremor is visual and goes from + to ++++. 
B) Rotarod analysis, performed at 3 months of age, shows that Mpz
D61N/+
 mice have a 
latency to fall of 184,7 s ± 14,21, compared to 329,7 s ± 23,24 for WT (Two-way 
ANOVA corrected for multiple comparison using statistical Sidak test; P value < 
0,0001). 
C) Grip strength test, performed at 3 month of age, shows that Mpz
D61N/+
 mice have 
less strength in hind limbs. In particular the force needed to win their grasp is 82,68 ± 




Moreover, by three months of age, all the electrophysiological parameters were 
unrecordable in most neuropathic mice suggesting a severe conduction block; the 
few parameters recorded were significantly impaired: for examples, the MCV was 
39,34 ± 0,26 m/s in WT mice and 13,2 ±1,8 m/s in the only two Mpz
D61N/+
 mice in 




Figure 7: Electrophysiological parameters in WT and Mpz
D61N/+ 
mice at 1 month 
Electrophysiological recordings from 1 month WT and Mpz
D61N/+ 
mice: all the 
electrophysiological parameters recorded were significantly different between the two 
groups (Unpaired t-test; P value < 0,0001) In the lower part are presented the original 
recordings: flags indicate the onset and end of the cMAPs; Mpz
D61N/+ 
mice showed a 
dispersed morphology, a prolonged latency of both distal and proximal cMAP with a 
significant reduction of the nerve conduction velocities, , as well as a reduced cMAP 






 show a severe de/dysmyelinating phenotype 
The behavioral and neurophysiological analysis outlined above suggested that the 
Mpz
D61N/+
 mutation determined a dramatic impairment of nerve functionality. To 
further corroborate this, we performed morphological analysis on semi-thin 
Figure 8: Electrophysiological parameters in WT and Mpz
D61N/+ 
mice at 3 months 
Electrophysiological recordings from 3 months WT and Mpz
D61N/+ 
mice: all the 
electrophysiological parameters recorded were significant different between the two 
groups (Unpaired t-test; P value < 0,0001) The original redrawn recordings are 
presented and the trend of the tracks is similar to that recorded when they were 1 
month old. The table in the lower part showed the value of the different 
electrophysiological parameters in WT animals, while for Mpz
D61N/+ 
mice is indicated 
the percentage of animals in which the different parameters were unrecordable. 
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section from 1 month sciatic nerves stained with toluidine blue (Figure 9A). 
Mutant fibers showed a decrease of myelin thickness, typical of a 
de/dysmyelinating phenotype, as measured by g-ratio analysis, (g-ratio 0,72 ± 
0,01 in Mpz
D61N/+ 
mice vs 0,65 ± 0,01 in controls; P value 0,0027) (Figure 9B); 
moreover, we also noticed a reduction in myelinated axon diameter in Mpz
D61N/+
 
nerves as compared to WT control (Figure 9C), despite no differences in the 










 nerves were also characterized by the presence of tomacula 
like structures, basically absent in WT controls, that increase with time, from 80 ± 
24,19 to 222 ± 12,49 per nerve section (Figure 10A, B), supporting the 
progressive worsening of the phenotype already noted in the behavioral and 



















Figure 9: Morphological analysis of WT and Mpz
D61N/+
 sciatic nerves 
A) Images of semithin section of sciatic nerves from WT and Mpz
D61N/+
 mice at 1 month 
(Magnification: 100X; Scale bar: 5 μm). 
B) G-Ratio of WT and Mpz
D61N/+
 fibers was analyzed (Error bars, SEM; unpaired, 2-
tails, Student’s t test; P value 0,0027). 
C) Comparison between axon diameter of WT and Mpz
D61N/+
 fibers (Unpaired, 2-tails, 
Student’s t test; P value < 0,0001). 
D) Number of fibers in WT and Mpz
D61N/+
 sciatic nerves at 1 month and 6 months 
(Unpaired, 2-tails, Student’s t test; P value 0,93 and 0,08 respectively). 
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The analysis of osmicated teased fibers revealed that these myelin abnormalities 







 myelin abnormalities 
A) Reconstruction of a Mpz
D61N/+
 1 month and 6 months sciatic nerve; a magnification 
is present to better visualize the increase of tomacula-like structures. 
B) Number of myelin abnormalities in Mpz
D61N/+
 sciatic nerves at 1 month and 6 





present defects in myelin compaction 
To further characterize myelin abnormalities and myelin compaction, we 
performed electron microscopy analysis on transverse and longitudinal section of 
WT and Mpz
D61N/+
 sciatic nerves. On transverse section, mutant nerves displayed 
frequent abnormal thickening of the myelin sheath that appeared to compress the 
axon; in longitudinal section of mutant nerves were evident several foldings and 
hypermyelinating aspects of one myelinated axon (white star) (Figure 12A). 
Moreover, high magnification analysis revealed that in many of the mutant fibers 
myelin periodicity was altered. In fact, whereas WT fibers showed a consistent 
frequency in major dense line and intraperiod line, in Mpz
D61N/+
 nerves some 
myelin lamellae looked normally compacted (black bar), while other showed 
uncompaction and widening of the intraperiod line (white bar) (Figure 12B).  
 
Figure 11: Analysis of Mpz
D61N/+
 osmicated fibers 
Osmicated teased nerve fibers from a Mpz
D61N/+
 mouse. Focal myelin thickenings 
originate both at paranodal regions and at internodal regions (Magnification 40X). 
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 Figure 12: Electron microscopy of WT and mutant sciatic nerves 
A) Transverse and longitudinal section of a WT and Mpz
D61N/+
 sciatic nerves. White 
star indicate a myelinated axon with hypermyelinating aspects. Scale Bar: 5μm in 
transverse section, 2μm in longitudinal section. 
B) Transverse section of a WT and Mpz
D61N/+
 sciatic nerves. Black bar indicate myelin 
lamellae normally compacted, white bar indicate uncompaction and widening of the 
intraperiod line. Scale bar: 500nm. 
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Finally, by immuno-EM, using an anti-P0 antibody, we evaluated the amount of 
P0 expressed on the cell membrane in normal myelin as compared with the 
pathological samples (Figure 13A). This analysis suggested a reduction in the 
density of P0 molecules (ratio between the number of gold particles and the 
membrane surface) in the myelin of Mpz
D61N/+
 mice, decreasing from 33,07 ± 
1,469 in WT to 17,91 ± 1,219 particles per square micron in mutant nerves 
(Figure 13B). This reduction could be due to a reduction of myelin compaction or 
to a reduction of P0 that can reach the cell membrane.  
 
 
Analysis of myelin proteins in WT and Mpz
D61N/+ 
mice 
Figure 13: Immuno electron microscopy of WT and mutant sciatic nerves 
A) Transverse section of a WT and Mpz
D61N/+
 sciatic nerve. The amount of P0 on the 
cell membrane has been visualized using an anti-P0 antibody. Scale bar: 500nm. 
B) Density of P0 molecules calculated as ratio between the number of gold particles 
and the membrane surface (Unpaired t test. P value < 0,0001). 
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The 20-30% of the peripheral myelin is composed by proteins; in addition to the 
P0 protein, the other two most abundant proteins in the peripheral myelin are 
Peripheral Myelin Protein 22 (PMP22) and Myelin Basic Protein (MBP). PMP22 
is involved in the determination of myelin thickness and in the maintenance of the 
compaction of myelin sheaths, while MBP participate in the maintenance of the 
major dense line [15]. Given the defects in myelin structure and myelin 
compaction of the model, we analyzed the quantity of the principal myelin 
proteins extracting total proteins from 1 month and 6 months sciatic nerves of WT 
and mutant mice; we also analyzed mRNA levels of MPZ, MBP and PMP22 at 1 
month of age. As shown in western blots and in the quantification of protein 
levels, at 1 month MBP (even if not significantly) and PMP22 resulted decreased 
in mutant nerves, coherently with myelin defects previously shown, while MPZ 
levels didn't change; there were no significant differences in mRNA levels (Figure 
14A, B, C). At 6 months of age, protein levels analysis confirmed the reduction in 
MBP and PMP22 (Figure 14D). 
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Analysis of myelin pathways in WT and Mpz
D61N/+ 
mice 
Schwann cell myelination is regulated by different players, downstream of which 
there are important signaling pathways, such as the PI-3 Kinase/AKT/mTOR 
pathway and the ERK/MAPK pathway. We evaluated the phosphorylation of 
AKT and ERK in WT and Mpz
D61N/+ 
mice at 1 month of age. Both p-AKT and p-
ERK resulted decrease in Mpz
D61N/+ 
mice, indicating a defect in myelination 
(Figure 15A, B) 
Figure 14: Analysis of myelin proteins  
A) Western blot, protein quantification and mRNA level of MBP in sciatic nerves of 1 
month WT and Mpz
D61N/+
 animals (Error bars, SEM; unpaired, 2-tails, Student’s t test; 
P value 0,1357 and 0,2779 respectively). 
B) Western blot, protein quantification and mRNA level of PMP22 in sciatic nerves of 
1 month WT and Mpz
D61N/+
 animals (Error bars, SEM; unpaired, 2-tails, Student’s t 
test; P value 0,0055 and 0,5991 respectively). 
C) Western blot, protein quantification and mRNA level of MPZ in sciatic nerves of 1 
month WT and Mpz
D61N/+
 animals (Error bars, SEM; unpaired, 2-tails, Student’s t test; 
P value 0,2702 and 0,3723 respectively). 
D) Protein quantification for MPB, PMP22 and MPZ in sciatic nerves of 6 months 
WT and Mpz
D61N/+
 animals (Error bars, SEM; unpaired, 2-tails, Student’s t test; P 
value 0,0041; 0,0412 and 0,0555respectively). 
β-tubulin was used as loading control for protein analysis. 
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Analysis of UPR activation in WT and Mpz
D61N/+ 
mice 
Several MPZ mutations cause the mutant protein to be retained in the endoplasmic 
reticulum (ER), activating a canonical Unfolded Protein Response (UPR) [124, 
165-167]; the partial intracellular retention of mutant protein in vitro, led us to 
evaluate if the mutation Mpz
D61N/+ 
caused the activation of these mechanisms. We 
measured the expression of ER stress/UPR markers such as BiP, C/EBP-
Homologous Protein (CHOP), phosphorylated eukaryotic Initiation Factor 2 α (P-
eIF2α) and spliced X-box Binding Protein 1 (Xbp1s) in sciatic nerves at 1 month. 
Mpz
D61N/+
 nerves showed a trend towards higher levels for all the markers 
analysed as compared with WT nerves, suggesting an activation of UPR in mutant 
nerves (Figure 16A, B). However, by 6 months of age there is no more activation 
of BiP and P-eIF2α markers (Figure 16C), suggesting that this activation is a 












Figure 15: Analysis of two different myelination pathways in WT and mutant 
sciatic nerves 
A) Western blot analysis and protein quantification of phospho-AKT in sciatic nerves 
of WT and Mpz
D61N/+
 animals at 1 month (Error bars, SEM; unpaired, 2-tails, 
Student’s t test; P value 0,0062). 
B) Western blot analysis and protein quantification of phospho-ERK in sciatic nerves 
of WT and Mpz
D61N/+
 animals at 1 month (Error bars, SEM; by unpaired, 2-tails, 
Student’s t test; P value 0,0078). 
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NB-DNJ: a possible benefit for hyperglycosylated mutations in vitro and ex 
vivo models 
Recent papers [146] [168] suggested that gain-of-glycosylation mutations may 
benefit from imino-sugars administration, a class of compound potentially able to 
modify N-glycosylation of proteins. Therefore, we treated Hela cells expressing 
the D61N mutation with 750 µM NB-DNJ to assess if this compound was able to 
complement in vitro the phenotype, by improving the trafficking of the mutant 
Figure 16: Analysis of ER stress/UPR levels 
A) Western blot analysis and protein level for the UPR markers BiP and p-
eIF2α/eIF2α in WT and Mpz
D61N/+
 sciatic nerves at 1 month; calnexin was used as 
loading control (Error bars, SEM; unpaired, 2-tails, Student’s t test; P value 0,0028 
and 0,0203 respectively). 
B) qRT-PCR analysis on 1 month sciatic nerve extracts for CHOP, spliced Xbp1 and 
BiP. (Error bars, SEM; unpaired, 2-tails, Student’s t test; P value 0,0047; 0,0983 and 
0,0005 respectively) 
C) Protein levels of BiP and p-eIF2α/eIF2α in WT and Mpz
D61N/+
 sciatic nerves at 6 
months measured by densiometric analysis (Error bars, SEM; unpaired, 2-tails, 
Student’s t test; P value 0,1824 and 0,6476 respectively). 
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protein and cell adhesion. Immunofluorescence analysis suggested that the 
treatment ameliorated P0D61N protein trafficking, reduced its intracellular 
retention and improved adhesion, without affecting WT protein trafficking; 
interestingly, the treatment of cells with the compound seems to reduced the MW 
of mutant protein, as though there was a modification in glycosylation (Figure 17 




Figure 17: Treatment with NB-DNJ in in vitro  
A) Confocal images of HeLa cells expressing the mutant protein D61N before and 
after the treatment with NB-DNJ; the treatment ameliorates protein trafficking. 
B) Adhesion assay performed on HeLa cells treated with NB-DNJ, the non treated 
protein have been used as control (One-way ANOVA corrected for multiple 
comparison using statistical Tukey test). 
C) Western blot analysis of HeLa cells expressing the P0wt protein and the mutant 
protein D61N treated with NB-DNJ; the treatment reduced the MW of mutant protein. 
 69 
Based on these results, we tested NB-DNJ in an ex vivo system, by establishing 
myelinating organotypic DRG cultures from wild-type and Mpz
D61N/+
 13,5-day-
old embryos (Figure 18). In mutant DRGs cultures, the number of myelinated 
internodes tend to be reduced; mutant DRGs also presented frequent myelin 
swellings reminiscent of the tomacula-like structures we saw in nerves. 
 
 
We reasoned that NB-DNJ, by modulating N-glycosylation, could ameliorate the 
morphology of myelinated internodes; we treated WT and Mpz
D61N/+
 DRGs with 
50 µM and 100 µM NB-DNJ; DRGs treated only with ascorbic acid were used as 
control. Two weeks treatment with NB-DNJ appeared to partially rescue myelin 
abnormalities in a dose dependent way: myelin defects were reduced by 25% after 
the treatment with 50 µM, and by 50% with the higher dosage (Figure 19A). 
To better investigate this myelin abnormalities reduction, we performed a western 
Figure 18: DRG coculture from WT and Mpz
D61N/+
 embryos 
Images of WT and Mpz
D61N/+
 DRGs stained for MBP. In mutant cultures there are 
fewer and often abnormal myelinated internodes. 
Magnification: 20X; 100X 
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blot analysis on DRGs in the three different conditions (treated only with ascorbic 
acid or treated with 50 µM and 100 µM NB-DNJ). However, what we founded is 
that, after the treatment with NB-DNJ, the proteins P0 and MBP appeared 
reduced, suggesting that a partial reduction of total myelin proteins might 
contribute to the amelioration of myelin morphology (Figure 19B). 
 
  
Figure 19: Treatment with NB-DNJ in ex vivo models 
A) DRG cultures from WT and Mpz
D61N/+
 embryos treated with 50 µM or 100 µM 
NB-DNJ; myelin abnormalities seem to decrease. Quantification of myelin 
abnormalities before and after the treatment with NB-DNJ (One-way ANOVA 
corrected for multiple comparison using statistical Holm-Sidak test; P value < 
0,0001). 
B) Western blot analysis of DRG from WT and Mpz
D61N/+
 embryos treated with only 
ascorbic acid (AA) or also with NB-DNJ for 14 days. P0 and MBP were analyzed and 




Motor, sensory and cognitive functions of the nervous system require a rapid and 
precise impulse propagation; to allow this, in vertebrates, axons are surrounded by 
the myelin sheath. In the PNS, the plasma membrane of SCs forms consecutive 
wrappings around the axons to form myelin. In order to achieve this goal, SCs 
synthesize a huge amount of lipids and proteins. This event is strictly regulated, as 
alterations in the amount or in the (genomic) sequence of myelin proteins cause, 
in humans, peripheral neuropathies, known as Charcot-Marie-Tooth (CMT) 
disease. CMT represent a heterogeneous group of hereditary disorders and, with a 
prevalence of around 1:2500, is the most common inherited neurological 
condition. CMT is caused by mutations in genes that encode for different proteins 
with different functions, such as myelin compaction and maintenance or 
cytoskeleton formation, axonal transport or mitochondrial metabolism. The most 
common CMT type, accounting for ~50% of all CMTs, is CMT1A caused by 
duplication on chromosome 17p11.2, a region that includes the PMP22 gene; 
CMT1X is the second most common CMT type and is caused by mutations in the 
GJB1 gene. Finally, mutations in MPZ gene are estimated to account for ~5% of 
all CMT cases. Clinical manifestations of CMTs are heterogeneous, suggesting 
that multiple and different pathogenic mechanisms [169] are involved, rendering 
the finding of effective therapies very hard. Great advances in understanding the 
patho-biology of CMTs have been made, but to date no cure is available [109, 
169]. In particular, more than 200 different mutations in the sequence of P0, 
mostly in the extracellular domain, are associated with diverse phenotypic 
manifestations [121]. MPZ mutations, in fact, can give rise to different 
phenotypes: an early-onset phenotype, with onset of the disease during the 1
st
 
decade of life and characterized by very slow MNCV, a late-onset phenotype, 
with onset from the 2
nd
 decades of life and with a normal or minimally impaired 
MNCV, or a childhood-adolescent-onset, with motor and sensory symptoms 
during the 2
nd
 decades of life, and showing a slowly progressive course, with 
MNCV of intermediate range [123]. Among the different pathogenetic 
mechanisms, the activation of the Unfolded Protein Response is the most 
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extensively studied: this mechanism occurs when a mutated protein is retained 
into the ER and it has been estimated that it could play a role in about one half of 
CMT1B neuropathies [108, 170]. This also means that there are other mechanisms 
responsible for CMT. Indeed, another mechanism could be misglycosylation, that 
can cause the loss of the native glycosylation site, or the gain of a new 
glycosylation site [125, 126]. 
Misglycosylation, not only for CMTs, is an increasingly recognized 
pathomechanism: in fact, important papers [146, 147] have demonstrated that the 
generation of new glycosylation sites or the removal of constitutive ones are 
phenomena more frequent than expected. In particular, the analysis of mutation in 
577 genes coding for membrane proteins revealed that mutations causing a gain of 
glycosylation account for about 1,4% of all missense mutations [146]. While 
peripheral myelin is largely composed by glycoproteins, misglycosylation has 
never been investigated as cause of peripheral neuropathies; for this reason, we 
decided to fully investigate how peripheral myelination is affected by P0 
misglycosylation using in vitro and in vivo systems. 
 
In vitro analysis of hyperglycosylated and hypoglycosylated mutations 
We characterized the effects of P0 mutants predicted to cause loss- or gain- of 
glycosylation in different in vitro models. 
We studied different mutations that can be divided in two groups: 
 the mutations that create a second Asp122-X-Thr124 sequence and 










 the mutations located in the Asp122-X-Thr124 consensus sequence that 












All these mutation had been already reported in literature [126, 148-155], but in 
most of them misglycosylation was not really proven, as well as the consequences 
of this event have not been fully investigated.  
Through transient transfections of HeLa and Schwannoma rat cells, we studied 
mutant proteins tagged with EGFP: we demonstrated that the mutations that were 
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predicted to introduce a new glycosylation site generated proteins with a higher 
MW as compared to the P0wt, whereas the proteins predicted to lose the 
constitutive glycosylation site had a lower MW; we demonstrated also that in both 
cases the difference in MW was indeed due to the acquisition or loss of 
oligosaccharides. Another important difference founded between the two groups 
of mutant proteins were the localization: all the unglycosylated proteins reached 
the plasma membrane as the P0wt protein; instead, the hyperglycosylated proteins 
were partially retained intracellularly. The partial retention could be due to the 
steric hindrance caused by the second oligosaccharide that increase the MW 
compared to the P0wt and that could slow down the normal protein trafficking. As 
matter of fact, the correct trafficking of P0 is fundamental: in fact, only when the 
protein reaches the plasma membrane it can perform its adhesive function, while a 
mislocalized protein will severely impair its function and potentially cause a 
cellular toxicity. This impairment has been highlighted with the adhesion test: the 
hyperglycosylated proteins that are partially retained intracellularly showed a 
reduced adhesion capacity if compared to both P0wt and the unglycosylated 
proteins. The latter instead normally reached the plasma membrane and, in almost 
all cases, display a normal adhesion capacity, confirming the importance of a 
proper protein trafficking for the P0 protein. Moreover, the slowdown in protein 
trafficking is associated with an increased endocytosis of hyperglycosylated 
proteins, supporting the hypothesis of a greater instability of mutant proteins 
compared to the P0wt. 
Interestingly, the two groups of mutations in patients give rise to different 
phenotypes: it was reported that most the unglycosylated mutations were 
associated with a late-onset neuropathy in which there was a clear axonal 
involvement; instead, the hyperglycosylated mutations correlated with an early-
onset neuropathy, characterized by a demyelinating phenotype [126, 148-155]. 
However, two exceptions were reported: the D
118
N amino acidic substitution, 
that give rise to a mild hyperglycosylation, was founded in a family affected by 
CMT2 [154], while the T
124
K was founded in a patient with congenital 
hypomyelination neuropathy [150]; in this latter case, it was hypothesized that the 
mutated allele of the MPZ gene could have a dominant-negative effect. The 
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divergent phenotypes are the consequence of different mutations that modify P0 
protein function in different manners: the hypoglycosylated mutations do not 
impair directly the P0 function but probably interfere with the correct SC-axon 
interaction, unlike to what hyperglycosylated mutations do, that is to distort the P0 




, a knock-in model of CMT1B and hyperglycosylation 
Several animal models of CMT have been developed, some of them extremely 
close to the human pathology [171]. However, at the moment there are no animal 
models of hyperglycosylation available; so, we decided to generate a full knock-in 
mouse model carrying the hyperglycosylated mutation MPZ
D61N
. The model was 
generated by the Core Facility for Conditional Mutagenesis (CFCM) at the San 
Raffaele Scientific Institute, using the CRISPR/Cas9 technology. The MPZ
D61N
 
mouse model represent the first knock-in model of CMT generated using these 
technique. Thanks to the technology used for the generation, only the desired 
amino acidic substitution D
61
N has been introduced. Biochemical analysis of 
the P0 protein revealed the presence of the amino acidic substitution that 
introduce the second glycosylation site. 
The mice showed neuropathological evidence as early as P15: even if the mutant 
mice were viable and grew similarly to the WT, MPZ
D61N/+
 mice presented an 
evident tremor that interfered with their motor capacity which was reduced as 
compared to WT mice. Also from an electrophysiological point of view they 
appeared severely compromised: at 1 month of age, a dramatic reduction in nerve 
conduction velocity and in the cMAP were evident; the same analysis repeated at 
3 months of age showed a further worsening since the electrophysiological 
parameters were unrecordable in mutant mice. 
 
Morphological evidence in Mpz
D61N/+
 mice 
Dysmyelination and/or demyelination is an hallmark of CMTs caused by 
mutations in MPZ gene. The behavioural and neurophysiological analysis outlined 
above suggested that the Mpz
D61N/+
 mutation indeed determined a dramatic 




 mice showed de/dysmyelination: myelin thickness is reduced as 
compared to WT nerves and also axons diameter appeared reduced, confirming 
that the introduced mutation modified the correct structure and function of the 
protein. Another peculiarity of the nerves of these mice is the presence of 
tomacula-like structures, represented by axons on which myelin lamellae are 
repeatedly and redundantly wrapped causing focal myelin swellings. Interestingly, 
these structures increased in number with the age of mice, which could explain the 
dramatic worsening of the neurophysiology at 3 months and the motor 
impairment, since it is conceivable that all these abnormalities might interfere 
with the correct nerve conduction and, consequently, functionality. It is important 
to emphasize that these mice faithfully recapitulate the human pathology: in fact, 
in both patients carrying the D
61
N amino acidic substitution, sural nerves 
presented fibers surrounded by thin myelin sheaths, tomacula-like structures and 
also fibers with abnormally compacted myelin [126, 152]. It might seems 
paradoxical that the same mutation can give rise to different phenotypes: 
demyelination on one side, and redundant myelin on the other. As already 
reported in literature [172, 173] the presence of both pathological features could 
suggest that the pathomechanism underlying the loss of myelin compaction and 
the myelin redundancy may be the same; alternatively it is possible that the 
amount of mutant protein reaching the cell membrane could cause myelin 
uncompaction, while the retained amount could cause a misregulation in myelin 
protein expression leading to demyelination. 
Tomacula-like structures, together with outfoldings or infoldings, have been 
already described in other CMT models [159, 174, 175], and are considered 
pathognomonic in CMT4B, a severe recessive form of CMT, caused by mutations 
in genes coding for Myotubularin 2 or 13. However, the pathogenic mechanism 
that cause this myelin abnormalities is still unknown. Tomacula-like structures are 
characterized by myelin that, in addition to being redundant, is also uncompacted. 
P0 contributes to form the intracellular “major dense line”; to fulfil this function, 
the extracellular domain contains a conserved sequence that has a role in 
mediating homophilic P0 interaction. However, crystal structure analysis of P0 
indicates that this region is also implicated in the formation of P0 homotetramers 
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in trans, keeping together the adjacent wraps of myelin. The presence of an extra 
glycan, with its steric hindrance, could interfere with myelin compaction and this 
could cause the uncompaction observed in the myelin in nerves of Mpz
D61N/+
 mice. 
Differently from other mice model [174], we founded that this tomacula-like 
structures are not prevalently present at the paranodal regions, but they are 
distributed along the entire internode. By immuno-EM we measured the amount 
of P0 expressed on the cell membrane and we found that the quantity of P0 in 
mutant nerves was reduced as compared to the amount of P0 in WT myelin. This 
could be due to the reduction of myelin compaction (that would increase the 
surface) or to the reduction of P0 that can reach the plasma membrane: in fact, 
either the increase in myelin lamellae distance, or the partial retention of the P0 
might explain this reduction. However, the fact that the mice carry both the P0wt 
and the MPZ mutation, did not allow us to better dissect the in vivo trafficking of 
the mutated protein. 
Myelin in PNS contains a huge amount of proteins: the principal two proteins, in 
addition to P0, are MBP and PMP22 that, even if in a different way, are both 
involved in the formation and/or maintenance of the myelin. MBP, that is 
localized in the major dense line of compact myelin, has an important role in the 
compaction and maintenance of myelin and it interacts with lipids of the 
membrane [15]. However, in the PNS MBP is not necessary for the formation of 
myelin lamellae while in CNS, mice lacking MBP showed defects in myelin 
compaction [176]. PMP22 is localized in compact myelin and has a role in myelin 
formation and maintenance; it mediates both homophilic interaction between 
PMP22 molecules and heterophilic interaction with P0. The defects in myelin 
compaction found in our model led us to analyze also these two proteins: despite 
no differences in mRNA levels, the overall amount of proteins from mutant 
nerves appeared reduced as compared to WT nerves. It was already reported that 
both P0 and PMP22 proteins are targeted to the plasma membrane in which they 
are inserted into the same sites, providing a possible explanation why mutations in 
either one of these genes share common phenotypes: in some patients, 
heterozygotes for the mutated gene, the myelin is initially formed, but later loss of 
compaction and demyelination proceeds, indicating that a lower amount of 
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functional protein is not sufficient to sustain a compact myelin sheath [177]. 
Indeed, mutations in P0 and PMP22 could also produce congenital 
hypomyelination neuropathy [178, 179]. This correlation between P0 and PMP22 
might explain why also in our model in which the mutation is in P0, we observed 
a large reduction also of PMP22. Interestingly, it was reported that PMP22/+ 
mice, that are models for the inherited human peripheral neuropathy HNPP, are 
characterized by tomaculous neuropathy with multifocal thickenings of the myelin 
sheaths, with evidence of para- and internodal tomacula in teased fibers [70]. The 
morphological similarities between PMP22/+ mice and Mpz
D61N/+
 mice sustain 
the hypothesis that the decrease in PMP22 protein levels that we observed in 
sciatic nerves of Mpz
D61N/+
 mice could be one of the factors causing 
morphological defects described above. Another interesting similarity between P0 
and PMP22 is that both proteins have a single L2/HNK1 epitope, which is known 
to participate in adhesive interactions. Indeed, even if the glycosylation is 
functionally important [180], it does not seem to be essential for either the 
homophilic P0-P0 [181] or heterophilic P0-PMP22 interactions; thus, the precise 
function of this sugar moiety is still unclear. 
 
Analysis of different pathways present in Mpz
D61N/+
 model 
PNS myelination is tightly regulated by NRG1 type III and by different pathways 
that are activated downstream of NRG1 type III such as PI-3 Kinase/AKT/mTOR 
pathway [39], the ERK/MAPK pathway [42], the cAMP signalling [43] and the 
Calcineurin/NFAT signalling [44]; however, the precise mechanism that drives 
myelination and differentiation is not completely understood. The PI3-kinase 
pathway activates two different responses in SCs: the first depends upon NRG1 
type III activation and induces myelination, whereas the second may negatively 
influence myelination [39]. Another pathway that participate to PNS myelination 
is ERK1/2 signaling, but also in this case with a dual role: ERK1/2 ablation 
during development was shown to impair SC differentiation and myelination [42], 
while the activation of the pathway led to increased myelin growth [182, 183]. In 
our mouse model, the phosphorilation of AKT and ERK, and so their activation, is 
decreased in respect to the WT; this suggest that the mutation somehow 
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determines a dysregulation of the pathways that control myelination. 
The partial intracellular retention of the mutated protein led us to also evaluate the 
activation of the Unfolded Protein Response (UPR). This pathway is of particular 
interest because recently different molecules that can attenuate the protein 
retention in the ER and the subsequent activation of the UPR have been identified 
[50, 184-186], pointing at the modulation of the UPR as a possible therapeutic 
avenue; as such it was important to understand if the pathway was active in our 
mouse model. We evaluated the protein levels of two component of the UPR 
pathway, as BiP and phospho-eiF2α at 1 month and 6 months of age in WT and 
mutant mice: at 1 month protein levels were mildly increased in mutant mice, 
indicating the activation of the pathway; however, at 6 months of age, protein 
levels were comparable with WT, suggesting that this pathway is only transiently 
activated. Normally the activation of the UPR is much stronger than what we 
observed in the Mpz
D61N/+
 model and appears to be constant during time [50, 166, 
167], indicating that UPR is probably not the principal mechanism that causes the 
pathology. 
 
NB-DNJ: a possible treatment for hyperglycosylation? 
The current lack of effective therapies always leads us to seek new strategies for 
the treatment of CMT. The use of a class of compounds belonging to the imino-
sugar category was proposed as a potential treatment for gain of glycosylation 
mutations [168, 187]. These molecules would be able to interfere with specific 
enzymes involved in the protein glycosylation chain, such as Golgi and 
endoplasmic reticulum glycosydases [188]. Among these molecules, N-butyl-
deoxynojirimycin (NB-DNJ) is a very interesting drug that has already been used 
for different disorders with a good safety profile in humans. Miglustat, the 
commercial name of the molecule, is used for the treatment of cyctic fibrosis 
[189], Gaucher disease [190] and Niemann-Pick disease, a lysosomal storage 
pathology [191]. Miglustat prevents the enzyme glucosylceramide synthase, 
involved in the first step of the production of glycosphingolipids, thus reducing  
the synthesis of glycosphingolipids in cells. Moreover, Miglustat inhibits the N-
glycan processing enzyme α-glucosydases I and II, localized in the ER. 
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The treatment with Miglustat of cells transfected with the mutated protein 
revealed an amelioration of the protein trafficking that appeared to be less 
intracellular retained. Further experiments showed also that cell transfected with 
the mutant protein showed a partial rescue of adhesive capacity after Miglustat 
treatment; importantly, also the MW of the protein after treatment was decreased, 
indicating that probably the treatment was effectively acting on the glycan 
composition, restoring the normal structure of the protein.  
To better evaluate the effect of this treatment and before using Miglustat for the 
treatment of Mpz
D61N/+ 
mice, we tested this drug on organotypic Dorsal Root 
Ganglion (DRG) coculture, a system in which SCs and neurons are both present, 
thus better modeling the human disease. We established DRGs cocultures from 
WT and mutant embryos and we observed that in mutant DRGs the myelinated 
tracts were less in number; interestingly, we also confirmed in this system the 
morphological defects typical of this mouse model: in fact, the myelinated tracts 
of DRGs from mutant embryos present many myelin abnormalities and appeared 
like a "string of pearls", due to the presence of focal enlargements of the myelin. 
So both features appear to be maintained, confirming us that this is indeed a good 
system on which testing potential treatments.  After treatment with Miglustat, the 
morphology of mutant organotypic DRG cocultures did change significantly since 
the number of myelin tracts presenting myelin abnormalities was reduced by 25% 
after the treatment with the lower concentration of NB-DNJ, and by 50% with the 
higher dosage. This first results made us hope to have found  a potential drug for 
the treatment of hyperglycosylation. However, WB analysis revealed that in 
DRGs, Miglustat did not appear to modify the glycosylation of P0, since the MW 
of the mutant P0 did not change after the treatment. Indeed, we also found that the 
quantity of another myelin protein such as MBP was reduced with the treatment; 
we therefore reasoned that the overall reduction in myelin proteins could explain 
the morphological rescue, likely due to a decrease in myelin production rather 
than to a correction of glycosylation. 
Therefore, we think that  it would be important to perform a mass spectrometry 
experiment to characterize the extra glycan introduced with the mutation and also 
the native oligosaccharide. Only in that way, we could better understand how to 
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act in a targeted manner. 
In conclusion: we investigated in vitro the effects of P0 mutants causing gain- or 
loss- of glycosylation and confirmed that mutations predicted to cause a gain- or 
loss- of glycosylation corresponded to hyper or unglycosylated P0 mutants. 
Further,  we studied for each P0 variant the trafficking through the secretory 
pathway and the effect of the changed amino acid on the adhesive function of P0, 
thus establishing a precise genotype-phenotype correlation. Indeed, most 
mutations causing a loss of glycosylation were associated with a late-onset 
phenotype and a mild cellular phenotype, whereas the majority of mutations 
associated with a gain of glycosylation, caused a severe, early-onset neuropathy 
with significant consequences on P0 trafficking and adhesive properties; these 
data confirm previous observations that, in general, losing a glycosylation site is 
less harmful than acquiring a new one.  
Then we established a murine model of MPZ
D61N 
mutation to evaluate in vivo the 
effects of hyperglycosylation. This is the first transgenic mouse, obtained with the 
CRISPR/Cas9 technique, expressing a gain-of-glycosylation mutant, providing a 
model of CMT1B due to hyperglycosylation of P0.  
Therefore, through in vitro, in vivo and ex vivo experiments, we established the 
ultimate link between P0 misglycosylation and peripheral nerve impairment and 
we performed preliminary experiments to evaluate a specific therapy for this 
pathomechanism. All our results may have implications for other diseases caused 
by hyperglycosylation such as rare mutations causing Cystic Fibrosis, different 
immunodeficiencies [146] and myoclonus-dystonia, due to a gain-of-
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Abstract
Mutations of myelin protein zero gene (MPZ) are found in 5% of Charcot–Marie–Tooth patients. In 2004, Shy et al. identi-
fied two main phenotypes associated with them: an early-onset subtype with mainly demyelinating features and a late-onset 
subgroup with prominent axonal impairment. We evaluated whether novel MPZ mutations described in literature during 
the last 14 years could still fit with this classification. We collected and revised reports of 69 novel MPZ mutations. Almost 
90% of them could be alternatively classified as responsible for: (a) an early-onset phenotype, with first limitations starting 
before 3 years (2.5 ± 0.50 years), motor milestones delays, frequently severe course and upper limb MNCVs below 15 m/s; 
(b) late-onset neuropathy, with mean age of onset of 42.8 ± 1.5 years and mean upper limbs motor nerve conduction velocities 
(MNCVs) of 47.2 ± 1.4 m/s; (c) a phenotype more similar to typical CMT1A neuropathy, with onset during the 2nd decade, 
MNCV in the range of 15–30 m/s and slowly progressive course. The present work confirms that P0-related neuropathies 
may be separated into two main distinct phenotypes, while a third, relatively small, group comprehend patients carrying 
MPZ mutations and a childhood-onset disease, substantiating the subdivision into three groups proposed by Sanmaneechai 
et al. (Brain 138:3180–3192, 2015). Interestingly, during the last years, an increasing number of novel MPZ mutations caus-
ing a late-onset phenotype has been described, highlighting the clinical relevance of late-onset P0 neuropathies. Since the 
family history for neuropathy is often uncertain, due to the late disease onset, the number of patients carrying this genotype 
is probably underestimated.
Keywords Charcot–Marie–Tooth · Myelin protein zero · Phenotype classification · Genotype–phenotype correlation
Introduction
Charcot–Marie–Tooth disease (CMT), with a prevalence of 
9.37–20.1/100.000 [1], is one of the most common heredi-
tary disorders of the nervous system. The clinical hall-
marks of the disease are distal weakness, muscle wasting 
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and sensory loss; nevertheless, the clinical phenotype can 
be quite variable in terms of age of onset, disease progres-
sion and severity. Based on nerve conduction velocity, CMT 
can be distinguished into two main forms: demyelinating 
(CMT1), characterized by upper limb motor nerve conduc-
tion velocities (MNCVs) below 38 m/s, and axonal (CMT2), 
with preserved or mildly slowed nerve conduction veloci-
ties in the upper limbs (> 38 m/s). From a molecular point 
of view, CMT is a complex disorder, with more than 1000 
putative mutations in 80 different disease-associated genes 
[2]. Mutations in myelin protein zero gene (MPZ), encod-
ing for P0, are found in 4.1% of all CMT patients [3, 4], and 
were initially described as responsible for CMT1B; subse-
quently, mutations in this gene have been found also in cases 
of congenital hypomyelinating neuropathy/Dejerine Sottas 
disease and CMT2. To analyse the phenotypes associated 
with MPZ mutations, Shy et al. [5] evaluated patients seen 
in their clinic and re-evaluated clinical data from 64 cases 
of CMT1B reported in literature until 2004. They found that 
most patients could be classified as having either an early-
onset or a late-onset neuropathy, the former presenting with 
onset of the disease during the 1st decade of life and with 
upper extremity MNCVs lower than 15 m/s, the latter with 
an age of onset over 20 years of age and with upper extrem-
ity MNCVs faster than 30 m/s. In a more recent work exam-
ining clinical severity of patients from Inherited Neuropathy 
Consortium [6], 47 MPZ mutations, of whom 15 were novel 
and 6 were described in literature after 2004, were classified 
as responsible for three phenotypes with onset in infancy, 
childhood and adulthood, respectively.
In the present study, we collected literature data related to 
novel MPZ mutations described between 2005 and 2018 to 
assess whether the distinction between early- and late-onset 
neuropathy can still be considered a landmark and to provide 
further insight into the disease mechanisms.
Methods
Literature evaluation
Reports about novel MPZ mutations described between 2005 
and 2018 were collected from a search on PubMed and on 
the online database http://molge n-www.uia.ac.be/CMTMu 
tatio ns/. We used the following search terms: “myelin pro-
tein zero”, “Charcot–Marie–Tooth disease”, and “novel 
MPZ mutation”. Reports of novel MPZ mutations not pro-
viding adequate clinical and neurophysiological data, i.e., 
a complete description of the clinical presentation and an 
upper limb neurophysiological study were excluded (Fig. 1). 
Mutations described by more than one author and associ-
ated with more than one phenotype were included in each 
of the described groups. MPZ mutations found in patients 
with a negative or not available family history were included 
if segregation analysis had been performed or if the muta-
tion was absent in unrelated healthy controls. For each 
mutation, clinical (age of onset, number of affected fam-
ily members, severity and additional clinical features) and 
neurophysiological data (upper and lower limbs motor con-
duction velocities and compound motor action potentials) 
Fig. 1  Flowchart of the inclusion process for the review
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were derived from the considered study for all the available 
patients. Mutations were classified as responsible for early-, 
childhood–adolescence- or late-onset neuropathy according 
to age of onset of the neuropathy (≤ 5 years, 6–20 years; 
≥ 21 years), defined by the age at which the proband or 
another family member started to manifest clinical and/or 
neurophysiological signs; for each group, average values and 
standard error were calculated for the considered variables. 
The severity of the disease was classified based on CMTNS, 
when reported, or on clinical aspects described in the report.
Results
Between 2005 and 2018, 76 novel MPZ mutations in 203 
patients have been reported in the literature [6–51] as 
responsible for Dejerine–Sottas disease, congenital hypomy-
elinating neuropathy, CMT1B or CMT2 neuropathies. We 
excluded three mutations described in five patients for 
insufficient clinical and neurophysiological data and one 
report about one variant of unknown significance (Figs. 1, 
2; Supplementary Table 4); three reports [21, 29, 47] on 
MPZ copy number variation in 14 patients were considered 
separately (Supplementary Table 5). Reports about 69 novel 
MPZ mutations in 180 patients contained adequate clinical 
and neurophysiological data, thus allowing us to derive the 
phenotype, including a group of 15 novel MPZ mutations in 
18 patients newly described in 2015 [6] and whose pheno-
type had already been classified has responsible for early-
onset, CMT1B or late-onset neuropathy (Fig. 1).
Overall, 60 out of 69 mutations (87%) in 144 patients 
could be unambiguously classified, according to clini-
cal and neurophysiological parameters, as responsible for 
an early-onset neuropathy (35 patients—24%; 23 muta-
tions—38%), a late-onset neuropathy (74 patients—51%; 
27 mutations—45%) or a childhood-onset phenotype (36 
patients—25%; 10 mutations—17%). Six (9%) other muta-
tions in 18 patients (10%) have been described in more than 
one report and associated by the authors to more than one 
phenotype and were therefore considered in each of the 
described groups; eventually, 3 further MPZ mutations (4%) 
in 14 patients (7%) were associated with an atypical pheno-
type [14, 20, 48] (Fig. 2).
From the descriptions of MPZ mutation in the literature, 
excluding those already classified in 2015 [6], we can derive 
as follows (Table 1, Fig. 3).
Twenty-six patients with 15 different novel mutations 
could be classified as having an early-onset neuropathy 
(Table 2). Among them, 17 patients with eight different 
mutations were described by the authors as having DSS, 
five patients with four different mutations were described 
as affected by CHN, and four patients with three different 
Fig. 2  Venn diagram show-
ing mutations included and 
excluded from the review
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mutations received a diagnosis of CMT1. The mean age 
at onset was 2.5 ± 0.50 years (median 2 years; range 0–9), 
with eight cases where the neuropathy started within the 
2nd year of life and seven patients presenting at birth as 
floppy babies. Family history was negative in the nine cases 
(60%) and six families (40%) with at least two affected mem-
bers were described. A severe clinical course, defined by a 
CMTNS > 20 was associated with 13 mutations in 19 cases 
(76%); 2 mutations in 6 cases were responsible for a mild 
to severe neuropathy. The phenotype was complicated by 
the occurrence of kyphoscoliosis in six patients (24% of 
patients, 33% of all mutations). Cranial nerves involvement 
was reported for several patients with early-onset neuropa-
thy. In particular, five patients carrying the His81Gln [13] 
mutation and one patient carrying the Ile30Thr mutation 
[19] showed Adie’s pupils, while two patients carrying the 
Gly137Gly mutation [50] had sensory-neural hearing loss 
and ptosis as adjunctive features. Neurophysiology was con-
sistent with a severe hypo- or demyelinating neuropathy with 
secondary axonal degeneration. All but three cases presented 
with MNCV of the median and ulnar nerves below 15 m/s, 
with mean MNCV of the median nerve of 7.4 ± 1.2 m/s; 
three patients showed absence of sensory and motor nerve 
responses both in upper and lower limbs. When obtainable, 
conduction velocities from lower limbs were similar to those 
obtained from the upper limbs. Compound muscle action 
potentials (CMAPs) and sensory nerve action potentials 
(SNAPs) were reduced, with mean CMAP = 1.8 ± 0.4 mV.
Seventy-six patients carrying 27 novel mutations could be 
classified as affected by a late-onset neuropathy (Table 3). 
In most cases, symptoms ensued after the 4th decade of life, 
and in several cases they started during the 6th or 7th dec-
ade (median 43 years; range 15–75; mean age of onset of 
42.8 ± 1.5 years). Family history was negative in 33% of the 
cases. Emerging features of late-onset P0 neuropathy were 
consistent with a sensory-motor neuropathy with prominent 
involvement of lower limbs and causing a relatively low 
disability, with 56 patients (78%) having a slowly progres-
sive, mild neuropathy (CMTNS < 10). Nevertheless, cases 
of rapidly progressive symptoms, appearing late in life but 
quickly conducting to severe disability and ambulation aid 
requirement have been described for Arg36Gly, Pro70Ser 
and His81Leu mutations [15, 27, 29]. Moreover, neuropathic 
pain was a prominent feature in several cases of late-onset P0 
neuropathies, as in the case of Arg36Trp [11] and Arg36Gly 
[15]: in both cases, patients started to complain of spontane-
ous burning pain and tingling of hands and feet, and showed 
neurophysiologic features of an axonal sensory-motor neu-
ropathy in all limbs. Additional clinical findings included 
slow or absent pupillary light reflexes in one patient carry-
ing the Phe95Leu mutation [38], and sensory-neural hear-
ing impairment in five patients harbouring the Phe95Leu, 
Pro105Thr or Arg106Cys mutations [23, 33, 37].
Electrophysiological analysis was consistent with an 
axonal neuropathy, with mean MNCV from ulnar nerve 
of 47.2 ± 1.4 m/s, and normal CMAP amplitudes from the 
upper limbs. Lower limbs neuronography, when recorded, 
was consistent with an axonal neuropathy (mean CMAP of 
common peroneal nerve = 2 ± 0.5 mV).
Forty-four patients with 14 different mutations presented 
a childhood–adolescence-onset phenotype that fits neither 
with an early- nor with a late-onset neuropathy, resembling 
rather CMT1A (Table 4). Usually patients showed a nor-
mal motor development and started to complain of sensory-
motor symptoms during the 1st or 2nd decade of life, with 
a mean age of neuropathy onset of 15.1 ± 1.1 years (median 
15 years; range 6–40). Nine cases were familiar (64%) and 
five sporadic (36%). The clinical course of disease within 
this group was mild in 82% of the cases, with a mean age of 
39.1 ± 3.3 years at first neurological visit, usually 2 decades 





Mutations (N) 15 14 27
Patients 26 44 76
Families 6 (40%) 9 (64%) 18 (66%)
Sporadic cases 9 (60%) 5 (36%) 9 (33%)
Age of onset (years) 2.5 ± 0.50 15.1 ± 1.1 42.8 ± 1.5
Pupillary abnormalities Six patients with two mutations 0 One patient with one mutation
Hearing loss Two patients with one mutation 0 Five patients with three mutations
Scoliosis 6 (24%) 0 0
CMTNS ≤ 10 3 (12%) 36 (82%) 59 (78%)
CMTNS 11–20 3 (12%) 8 (18%) 12 (16%)
CMTNS > 20 19 (76%) 0 5 (7%)
Mean UL mNCV (m/s) 7.4 ± 1.2 31.2 ± 2.6 47.2 ± 1.4
Mean UL CMAP (mV) 1.8 ± 0.4 6.6 ± 0.6 8.3 ± 0.7
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after first signs or symptoms’ onset. Only eight patients with 
six mutations experienced a neuropathy of moderate sever-
ity (CMTNS 10–20). Cranial nerves involvement was never 
reported and patients had no additional features other than 
the polyneuropathy. Neurophysiological examination was 
consistent with a demyelinating polyneuropathy with MNCV 
approaching the so-called intermediate range, a mean ulnar 
nerve MNCV of 31.2 ± 2.6 m/s, and usually preserved upper 
limbs CMAP (6.6 ± 0.6 mV).
Eventually, four mutations were associated with a phe-
notype slightly different from the classical ones (Table 5): 
Gly103Gly synonymous mutation [14] has been described in 
two families with variable age of onset, neuropathic pain and 
predominant sensory involvement; Arg67Pro [20] has been 
described in a family with a compound genotype and pheno-
type of periodic palsy and myotonia, Leu48Pro [49] has been 
reported in two families with high intrafamilial variability 
in terms of age of onset, electrophysiological findings and 
Fig. 3  Mutations in the MPZ 
gene associated with inher-
ited neuropathies. Adhesive 
interface, fourfold interface and 
head-to-head interface, marked 
with colour to the border of cir-
cle, refer to amino acid residues 
deemed essential for cis and 
trans adhesion between adjacent 
myelin wraps. Both the number-
ing systems for MPZ mutations, 
including or not the 29 amino 
acid leader peptide cleaved 
before insertion in the myelin 
sheath, are reported. Mutations 
demonstrated by adding the 
letters that represent amino acid 
change, arrows that repre-
sent frameshift mutation and 
lines that represent nonsense 
mutation. Mutations causing 
early-onset phenotype are filled 
or noted with red colour, while 
those causing childhood-onset 
phenotype are in orange, and 
those causing late-onset pheno-
type are in purple (updated from 
Sanmaneechai et al. [6])
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severity of the disease. Moreover, Tyr145 fs has been found 
by two different groups, in one case in a family with classi-
cal CMT2 phenotype [32], in the other [31] in three patients 
from one family with onset during the 4th decade of life and 
electrodiagnostic and pathologic findings of HNPP. In all the 
atypical cases, the identified mutation segregated with the 
disease in the families.
In addition to the classical small intragenic muta-
tions, cases of MPZ copy number variation have recently 
been described (Supplementary Table 5). Hoyer [21] first 
described a family carrying an extra copy of the MPZ gene 
from exon 1 to exon 6, associated with a demyelinating neu-
ropathy with onset within the 1st decade of life and slowly 
progressive course, while Maeda [30] described a family 
carrying MPZ triplication, affected by a demyelinating sen-
sory-motor neuropathy with pupillary abnormalities and 
high intrafamilial heterogeneity in terms of age of onset and 
disease severity. Recently, Speevak [48] reported another 
case of MPZ duplication in a child affected by motor hypo-
demyelinating neuropathy with onset during the 1st year of 
life and a copy number variation of a region including MPZ 
and succinate dehydrogenase complex subunit C (SDHC) 
genes.
Six patients among all those included in our study, six 
carrying late-onset variants (Arg36Trp, Cys50Gly, Ser54 fs, 
Asp224Tyr, Arg36Gly, Val136Gly) [11, 12, 15, 36, 41, 43] 
initially received a diagnosis of inflammatory neuropathy, 
given an acute/subacute fluctuating clinical course eventu-
ally associated with pain as a prominent feature, markedly 
increased CSF protein concentration, and diffuse hypertro-
phy and slight gadolinium enhancement of the cauda equina 
roots at MRI. Moreover, co-occurrence with multiple scle-
rosis or asymptomatic CNS myelin abnormalities has been 
described for the Asp224Tyr [17] and Val136Gly [41] muta-
tions, respectively.
Discussion
In this study, we aimed to define the spectrum of MPZ-asso-
ciated phenotypes [5, 6] collecting and reviewing literature 
data regarding novel MPZ mutations described during the 
last 14 years (2005–2018), to better characterize the clinical 
features associated with them.
We identified 76 novel MPZ mutations associated with 
CMT in the recent literature. We excluded one VUS and 
other three mutations (5%) from the current work because 
of inadequate clinical data and considered separately three 
MPZ copy number variations (5%). Four mutations resulted 
in an atypical phenotype and six were described by more 
than one author as responsible for distinct phenotypes. The 
remaining 60 mutations, including 15 newly reported in a 
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carrying MPZ mutations recruited by the Inherited Neuropa-
thy Consortium in a natural history study, corresponded to 
either early demyelinating, a childhood demyelinating or the 
late axonal phenotype.
In more detail, one quarter of the cases presented an 
early-onset phenotype, manifesting during motor develop-
ment and characterized by very slow MNCV, while one 
half of the patients with novel MPZ mutations had an adult-
onset axonal neuropathy with normal or minimally impaired 
MNCV. Interestingly, another quarter of the cases evaluated 
in this study had a distinct phenotype, presenting with motor 
and sensory symptoms usually during the 2nd decade of 
life and showing a slowly progressive course, with MNCV 
in the lower limit of the intermediate range. Such a pheno-
type, definable as childhood–adolescence onset, has been 
also highlighted, with a similar percentage, by Sanmanee-
chai et al. [6].
Myelin protein zero is the most abundant protein of the 
peripheral compact myelin, where it maintains the cohe-
sion between adjacent myelin wraps through homophilic 
interactions [52]. As P0 is a prominent myelin protein, the 
mechanisms whereby MPZ mutations act in the generation 
of disorders alternatively affecting myelin or axons remain 
to be elucidated.
In the last years, different pathomechanisms for MPZ 
mutations have been dissected, particularly for mutations 
causing an early-onset neuropathy, ranging from endoplas-
mic reticulum retention and activation of the canonical 
unfolded protein response [53–56] to altered trafficking of 
the protein to non-myelin plasma membranes and altered 
radial axonal sorting during the early phases of myelina-
tion [57]. Other proposed mechanisms include the disrup-
tion of the intercellular adhesion properties with a structural 
packing defect [53] and mis-glycosylation of P0 with either 
loss of the native glycosylation site, the Asp122, frequently 
associated to a late-onset axonal neuropathy, or the gain of 
a new glycol site, resulting in an hyperglycosylated P0 vari-
ant, observed for mutations causing a severe demyelinating 
neuropathy [54, 58].
Advances have been achieved by the evidence that P0 not 
only localises in the compact myelin but also at the paran-
ode and node of Ranvier, where it interacts with neurofascin 
155 (NF155) and neurofascin 186 (NF186), participating in 
the maintenance of the nodal structure [59] and that Asp-
6Tyr, Asp32Gly, and His52Tyr mutations, responsible for 
late-onset CMT, display homophilic adhesion properties 
comparable to wild-type P0, but are unable to interact with 
components of the paranodal and nodal complexes.
CMT2 accounts for 30% of all CMT patients [60]. From 
our results, in the last decade, there was an increasing 
amount of novel MPZ mutations associated with late-onset 
axonal neuropathies rather than early-onset hypo- or demy-
elinating neuropathies. If we consider that while severe 
early-onset P0 variants often occur de novo and remain 
limited to a restricted number of cases, late-onset muta-
tions are frequently familial and involve a larger number 
of subjects and recessive transmission, usually more com-
mon in severe early-onset diseases, has been described 
as associated with a late-onset phenotype in a patient 
carrying Val136Gly mutation, located in the same resi-
due of Val136Glu but associated with heterozygous DSS 
and the prevalence of late-onset MPZ mutations, which 
has long been underestimated, is likely to be higher than 
expected, as growing awareness is increasing diagnostic 
rate and patients without overt family history may still be 
misdiagnosed.
Our data also include cases with presenting or super-
imposed features of an acquired inflammatory neuropathy. 
Given that the association between hereditary and inflam-
matory neuropathies is not yet clarified, and that neurophysi-
ological and laboratory findings once considered typical for 
acquired inflammatory neuropathies have been described 
in various forms of CMT, genetic causes, including MPZ 
mutations, should be considered in the workup of patients 
with features of inflammatory neuropathy, especially if not 
all diagnostic criteria for inflammatory neuropathies are ful-
filled and clinical response to immunosuppressive treatment 
is poor.
Molecular diagnosis of CMT can be achieved in 60–80% 
of cases [3, 56, 60, 61]. While up to 98% [56] of patients 
affected by CMT1 eventually receive a molecular diagnosis, 
this is still frequently challenging for patients suffering from 
late-onset CMT2, with the rate of diagnosis ranging between 
25 and 63% using a gene-by-gene approach.
During the last years, the landscape of mutations respon-
sible for CMT2 has expanded, ranging between the more 
common GJB1 heterozygous mutations and autosomal 
dominant GDAP1 mutations, and the incorporation of next-
generation sequencing in the diagnostic practice has allowed 
the discovery of novel CMT genes, especially causing late-
onset CMT2 [62], including HARS [63], MARS [64], MME 
[65] MORC2 [66] and NEFH [67].
The increasing amount of new genes associated with 
CMT2 and by the fact that other genetically determined 
neuropathies such as transthyretin-related amyloidosis, a 
systemic disease with involvement of peripheral nerves, 
can also manifest after the 6th decade, it is conceivable that 
an increasing number of late-onset neuropathies, previously 
misdiagnosed as acquired or age related, have a genetic 
cause.
In conclusion, our data, focusing on P0-related neuropa-
thies heterogeneity, confirms the existence of three distinct 
phenotypes deriving from MPZ mutations, and highlights 
the clinical relevance of late-onset P0 neuropathies as well 
as the need to increase our knowledge about their underlying 
molecular mechanisms.
2644 Journal of Neurology (2019) 266:2629–2645
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